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Abstract
Meta-analysis is an important and widely used tool for synthesizing information from mul-
tiple independent but related studies. While many meta-analyses, such as those of ran-
domized controlled trials, focus on the synthesis of treatment effects across studies, this
dissertation will focus on the meta-analysis of prevalence and normative data. The first
part of this thesis concerns the multivariate meta-analysis of prevalence data. When con-
ducting a meta-analysis involving prevalence data for an outcome with several subtypes,
each of them is typically analyzed separately using a univariate meta-analysis model. Re-
cently, multivariate meta-analysis models have been shown to correspond to a decrease in
bias and variance for multiple correlated outcomes compared with univariate meta-analysis,
when some studies only report a subset of the outcomes. Chapter 2 of this thesis proposes
a novel Bayesian multivariate random effects model to account for the natural constraint
that the prevalence of any given subtype cannot be larger than that of the overall preva-
lence. Extensive simulation studies show that this new model can reduce bias and variance
when estimating subtype prevalences in the presence of missing data, compared with stan-
dard univariate and multivariate random effects models. The data from a rapid review on
occupation and lower urinary tract symptoms by the Prevention of Lower Urinary Tract
Symptoms Research Consortium are analyzed as a case study to estimate the prevalence
of urinary incontinence and several incontinence subtypes among women in suspected high
risk work environments.
The second part of this thesis concerns estimating a reference range from a meta-analysis.
Clinicians frequently must decide whether a patient’s measurement reflects that of a healthy
“normal” individual. Thus, the reference range is defined as the interval in which some
proportion (frequently 95%) of measurements from a healthy population is expected to fall.
One can estimate it from a single study, or preferably from a meta-analysis of multiple
iii
studies to increase generalizability. This range differs from the confidence interval for the
pooled mean or the prediction interval for a new study mean in a meta-analysis, which do
not capture natural variation across healthy individuals. Chapter 3 proposes three methods
for estimating the reference range from a meta-analysis of aggregate data that incorporate
both within and between-study variations. The results of a simulation study are presented
demonstrating that the methods perform well under a variety of scenarios, though users
should be cautious when the number of studies is small and between-study heterogeneity is
large. These methods are applied to two examples: pediatric time spent awake after sleep
onset and frontal subjective postural vertical measurements. Chapter 4 provides a guide for
clinicians and epidemiologists explaining the three approaches for estimating the reference
range presented in Chapter 3: a frequentist, a Bayesian, and an empirical method. Each
method is also extended to individual participant data (IPD) meta-analysis, with the latter
being the gold standard when available. These approaches are illustrated using a clinical
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Meta-analysis allows for the synthesis of results across multiple independent studies and
therefore plays an important role in evidence-based medicine [1, 2]. The number of meta-
analyses published has increased sharply in the past several decades, increasing by 20-fold
between 1994 and 2014 [2]. New methods developed for meta-analysis include those for net-
work meta-analysis, which allows for the synthesis of studies assessing multiple treatments,
and multivariate meta-analysis, which allows for multiple outcomes [3]. In addition, many
methods have been developed for the evaluation of diagnostic tests [4–6]. However, while
meta-analyses often include the results of clinical trials or other experimental data, there are
many examples of meta-analyses of observational data, including prevalence and normative
data [7–14]. Normative data refers to data assumed to be drawn from a predefined healthy
population that can provide a reference when determining whether the measurements or
results in a new population are normal or not [15]. This thesis focuses on methods for
meta-analysis of prevalence data and normative data.
The second chapter of this thesis demonstrates how an arm-based network meta-analysis
model can be applied to the multivariate meta-analysis of prevalence data. It also proposes
a new parameterization that accounts for natural constraints in the data, decreasing bias
and increasing precision. There has been much work investigating the benefits of the joint
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meta-analysis of multiple related outcomes, particularly in the presence of missing data,
due to the multivariate models “borrowing strength” across outcomes [3, 16]. However,
there have only been several previous examples of multivariate meta-analysis of prevalence
data in the literature [10,11,17], none of which have accounted for natural constraints in the
underlying prevalences and observed counts when several outcomes are subsets of an overall
outcome. While Trikalinos et al. [18] proposed a multivariate meta-analysis model using
a multinomial distribution that could be applied for multiple category prevalences if the
outcomes were mutually exclusive, many prevalence outcomes with multiple categories are
not mutually exclusive, such as the proportion of individuals in a study with different types
of food allergies [13]. This is also true for the motivating example described in Chapter 2,
which consists of the results of a systematic review investigating the prevalence of women
in high risk working environments with different non-mutually exclusive types of urinary
incontinence: stress urinary incontinence and urgency urinary incontinence [19].
Chapter 3 proposes methods for establishing reference ranges for continuous measure-
ments from meta-analyses of normative data and illustrates them through several case stud-
ies. A reference range is defined as an interval that captures some predefined proportion
of measurements (such as 95%) from a healthy population that can serve as a reference for
future comparison. Alternatively, it can be defined as a prediction interval for the measure-
ment of a new individual [20, 21]. Previously, no guidance has existed in the literature for
how to estimate a reference range from a meta-analysis, particularly when only aggregate
data are available for each study. When conducting a meta-analysis to estimate a reference
range, practitioners can expect to have information on the observed mean, standard devia-
tion, and sample size of measurements from each study. There may also be some aggregate
demographic information, such as the proportion of males and females in the study, or the
mean age of participants. However, individual participant data (IPD) often are not avail-
able. Therefore, it is important to develop methods that allow for estimating a reference
range based only on the aggregate data. Chapter 3 will propose three such methods: one
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frequentist, one Bayesian, and one empirical, and demonstrate their performance through
simulations.
Finally, while Chapter 3 proposes three methods to estimate the reference range from a
meta-analysis, filling an important gap in the literature, it is aimed at a statistical, rather
than clinical audience. Therefore, in Chapter 4, we provide a guide for clinicians and
epidemiologists that introduces practitioners to the three methods proposed in Chapter 3.
This also demonstrates how these methods can be extended in the case IPD are available.
The differences between a reference range, a confidence interval for the pooled mean, and the
prediction interval for a new study mean are further explained, as some practitioners have
previously reported the pooled mean and its corresponding confidence interval as a“reference
value.” This chapter also considers ideas such as heterogeneity and applicability. When
estimating a reference range, it is important to carefully consider the target population
and establish inclusion and exclusion criteria that ensure the reference range will apply
to the population of interest. However, if the population of interest consists of several
distinct subgroups with different normal measurements, separate reference ranges for these
subgroups would likely be more informative. These concepts are illustrated through a
clinical scenario regarding the normal range for a non-invasive liver stiffness test.
Chapter 5 summarizes the findings in the previous chapter and describes future work
related to these topics.
3
Chapter 2
A Bayesian Multivariate Meta-Analysis
of Prevalence Data
2.1 Introduction
Meta-analysis plays an important role in synthesizing evidence from multiple sources, sup-
porting the recent rapid growth of “evidence-based medicine” [1]. Multivariate and network
meta-analysis (NMA) methods have been developed for meta-analyses of data consisting of
multiple outcomes, multiple treatments, or multiple diagnostic tests [3, 6, 18, 22–30]. NMA
uses both indirect and direct comparisons of multiple treatments within a network, while
multivariate meta-analysis allows for the joint analysis of multiple outcomes by incorpo-
rating information about their correlations [25, 27]. These models are therefore able to use
information normally unavailable when each treatment or outcome is analyzed separately, a
statistical concept known as “borrowing strength” that is particularly useful in the presence
of missing data [16,24,31]. For example, Williams and Bürkner (2017) [32] jointly modeled
the effects of intranasal oxytocin on multiple symptoms of schizophrenia in a Bayesian mul-
tivariate meta-analysis, resulting in increased precision compared to previous analyses that
modeled symptoms separately.
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Multivariate meta-analysis models have also been increasingly used in the evaluation of
diagnostic tests, as they allow for the joint modeling of accuracy indices such as sensitivity
and specificity [4, 5, 33–35]. The use of NMA in meta-analyses of clinical trials assessing
multiple treatments has also increased sharply over the past decade [27, 36, 37]. However,
many practitioners conducting systematic reviews involving multiple correlated outcomes of
interest still analyze these individually using separate univariate models, thus ignoring any
correlations between outcomes. Riley (2009) [16] suggested that reasons for this hesitancy
may include “tradition, the increased complexity of the multivariate approach, the need for
speciali[zed] statistical software and a lack of understanding of the consequences of ignoring
correlation in meta-analysis”, which are all still relevant issues.
This widespread use of separate univariate models is especially prevalent in the context
of observational data. For instance, we found only three examples of multivariate meta-
analysis of observational data in the literature: 1) Fawcett et al. (2018) [10] presented
a multivariate method that used data on prevalences of individual disorders in order to
estimate their overall prevalence. To our knowledge, this is the only study to perform a
multivariate meta-analysis of prevalence and incidence data. 2) The Fibrinogen Studies
Collaboration (2009) [11] used a bivariate random effects meta-analysis in order to jointly
model partially and fully adjusted estimates of the association between fibrinogen level and
incidence of coronary heart disease, and 3) Lin and Chu (2018) [17] proposed a Bayesian
multivariate meta-analysis simultaneously analyzing multiple factors. While meta-analyses
are most frequently conducted in order to estimate effect sizes such as odds ratios (OR’s),
risk differences, or mean differences, they can also be used to estimate the pooled disease fre-
quency such as incidence rates and prevalence proportions [38]. This may include multiple
related outcomes consisting of an overall prevalence and several subtypes of the measured
outcome. For example, Rona et al. (2007) [13] conducted univariate meta-analyses estimat-
ing the prevalence of any food allergy as well as the prevalences of specific types such as
allergies to peanuts and shellfish. Similarly, Williams et al. (2006) [14] separately estimated
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the prevalences of typical autism and all autism spectrum disorders (ASD). For this type
of data, it is reasonable to expect that the prevalence of any given subtype will be both
correlated with and constrained by the overall prevalence. Therefore, these outcomes are
not independent. Additionally, the subtypes measured in observational data may be par-
ticularly susceptible to outcome reporting bias (ORB). If a study is smaller or performed
in a population in which the overall prevalence is expected to be lower, investigators may
be more likely to only report the overall outcome [18].
Multivariate meta-analysis models have been shown to be effective in reducing ORB
when there is correlation between outcomes, in addition to providing more precise estimates
in the presence of missing data [16,18,27,31,39]. Modeling multiple correlated prevalences
using univariate models ignores studies in which each particular prevalence is not reported.
This can result in biased estimates if any of the studies are subject to ORB. Instead, mul-
tivariate models allow us to “borrow” information on missing observations across outcomes
using the within-study correlations [27]. However, one reason that practitioners may be
reluctant to use multivariate meta-analysis methods, is that these within-study correlations
have to be estimated [3]. In this paper, we address that issue through the use of a Bayesian
multivariate meta-analysis framework. This framework also gives us greater flexibility in
parameterizing the multivariate random effects model. Prevalences of individual subtypes
are subject to the natural constraint that they cannot be larger than the overall prevalence.
While Trikalinos et al. (2013) [18] jointly modeled multiple categorical outcomes that are
mutually exclusive or subsets of each other using a multinomial distribution, our method
differs in that the multiple subtypes modeled need not imply a set of mutually exclusive
categories. We introduce a case study as a motivating example in Section 2.2. We then
present fully Bayesian univariate and multivariate models for estimating the prevalence of
each outcome in Section 2.3, including a novel parameterization of the multivariate random
effects model that accounts for the natural constraints in the data, thereby incorporating
additional information into the model. We then compare these three different approaches in
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simulation studies (Section 2.5) and when applied to the case study (Section 2.6). Section
2.6.2 presents a sensitivity analysis of the missing at random (MAR) assumption for the
case study. Section 2.7 gives a brief discussion of these results.
2.2 A Motivating Study
Recently, members of the PLUS research consortium [40] conducted a rapid review of studies
reporting lower urinary tract symptoms in women in suspected high risk working environ-
ments [19]. Of the studies collected, 26 report the overall number of women in the study as
well as the number experiencing any form of urinary incontinence (UI). Additionally, many
studies provide data on two subtypes of UI: stress urinary incontinence (SUI) and urgency
urinary incontinence (UUI). We present the data in Table A.1, which was not included in
the original paper by Markland et al. (2018) [19]. Let yi0, yi1, and yi2 denote the number
of women experiencing any UI, SUI and UUI in study i, respectively, and let ni denote
the total number of women in each study. While all studies provide counts for the total
number of women experiencing any urinary incontinence, many studies do not report one
or both subtype counts. We note that yi0 ≥ yi1, yi2 and the counts for each subtype do
not necessarily sum to the overall UI count when they are all reported, as they are not
mutually exclusive. Therefore a model based on a multinomial distribution such as that
used by Trikalinos et al. (2013) [18] would not be appropriate. Our goal is to estimate
the population-averaged marginal prevalence of urinary incontinence (π0), as well as that
of each subtype (π1, π2).
Currently, standard practice would be to estimate each prevalence individually, using
univariate random-effects models. However, it is reasonable to expect that the prevalences of
the different subtypes of urinary incontinence outcomes will be correlated with one another,
in addition to being correlated with the overall prevalence. This can allow us to use data
from non-missing outcomes to address ORB and increase the precision of our pooled subtype
estimates. Therefore, we first fit a Bayesian multivariate random effects model in order to
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incorporate information about the correlations between the UI outcomes (π0, π1, π2). We
then compare these results to those found using a novel parameterization of the model that
incorporates the natural constraint that π0 ≥ π1, π2. Finally, we compare the results found
using both of these models to those found using separate univariate random effects models.
2.3 Methodology
2.3.1 A univariate random effects model
As mentioned previously, one way to model the overall and subtype prevalences of a con-
dition, is to model each using separate univariate random effects models [41]. In using
random effects models, we assume that the true prevalences vary across studies. Let πij be
the probability of having the jth outcome in study i ∈ {1, ..., N}, where j ∈ {0, 1, ..., J},
and let ni be the number of participants in study i. Here, πi0 refers to the overall prevalence
in study i, while πi1, ..., πiJ refer to the J subtype prevalences. Let Si be the set of outcomes
that are reported in study i, and Di = {(yij , ni), j ∈ Si} denote the available data from
study i. Let φ(z) and Φ(·) denote the probability density function and cumulative density
function (CDF) of the standard normal distribution, respectively. If we use a probit link
function to separately model the number of cases yij for each of the J + 1 total outcomes,
we have
yij ∼ Binomial(ni, πij),Φ−1(πij) = µj + vij , vij ∼ N(0, σ2j ), j ∈ Si, i = 1, ..., N, (2.1)
where µj is the fixed effect for each outcome, while vij is the random effect for outcome j
within study i. Therefore, σj describes the between-study variability in outcome j. If we
assume that conditional on the πij ’s, the yij ’s are independent, this gives us the following










yi [1− Φ(µj + σjz)]ni−yiφ(z)dz. (2.2)






[30], j ∈ {0, 1, ..., J}.
2.3.2 A multivariate random effects model
We can extend this univariate approach to jointly estimate the prevalences for multiple
outcomes, using a multivariate Bayesian random effects model. This incorporates the corre-
lations between outcomes to improve estimation when missing data are present, otherwise
known as borrowing strength. Zhang et al. (2014) [30] present a hierarchical Bayesian ran-
dom effects model with a probit-link in the context of “arm-based” network meta-analysis.
In “arm-based” NMA, the focus is on calculating the event probabilities for each treat-
ment arm [30, 42, 43]. Therefore, we adapt this framework in order to estimate the event
probabilities for our overall outcome and each of the subtypes, treating them as separate
“arms.”
We first let each yij be independently binomially distributed, conditional on πij . We
then let the probit-transformed (πi0, ..., πiJ)
T follow a multivariate normal distribution:




T = (µ0 + vi0, µ1 + vi1, ..., µJ + viJ)
T ,
vi = (vi0, vi1..., viJ)
T ∼MVN(0,ΣJ+1), j ∈ Si,
(2.3)
where ΣJ+1 = diag(σ)RJ+1diag(σ). RJ+1 is the within-study correlation matrix and
the σ2j terms capture the between study variation in each outcome. Let Lij denote the
conditional likelihood given vij , defined as
Lij(yij ;µj , vij) = [Φ(µj + vij)]
yij [1− Φ(µj + vij)]ni−yij . (2.4)
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where RJ is the J-dimensional real space. The population averaged prevalence for each






, j ∈ {0, 1, .., J}.
2.3.3 A new multivariate random effects model accounting for the natural con-
straint
While the above multivariate model allows us to incorporate information about the correla-
tion between outcomes into our estimation of the population-averaged prevalences, it fails
to account for the natural constraint in the data when we model an overall outcome along
with the prevalence of different subtypes. We present a different parameterization of the
previous model in order to account for this natural constraint: yi0 ≥ yi1, yi2, ..., yiJ , without
requiring the subtypes be mutually exclusive.
First, let yi0 be binomially distributed with parameter πi0 as for the other two ap-
proaches. Then, let pij denote the proportion of cases in study i that fall into the subtype
j ∈ {1, ..., J}. Therefore, yij is binomially distributed with denominator yi0 and probability
pij . Let µ0 denote the fixed effect for the overall outcome, and vi0 are the within-study
random effects for this overall outcome. Let µ∗j be the fixed effect corresponding to the
proportion of outcomes that fall into subtype j and the v∗ij ’s be the corresponding random
effects. We again use a probit link function to model πi0 and pij :
yi0 ∼ Binomial(ni, πi0),Φ−1(πi0) = µ0 + vi0,
yij ∼ Binomial(yi0, pij),Φ−1(pij) = µ∗j + v∗ij , j ∈ {1, ..., J}, j ∈ Si,








where Σ∗J+1 = diag(σ
∗)R∗J+1diag(σ
∗). R∗J+1 is the within-study correlation matrix
and the σ∗2j terms capture the between study variation in the overall outcome and proportion
of events that fall into each subtype. The key difference between ΣJ+1 and Σ
∗
J+1 is that the




J+1 describe the within-study random effects




while σ21, ..., σ
2
j in ΣJ+1 describe the within-study random effects in the prevalences of the
individual subtypes (vi1, ..., viJ)
T . Furthermore, the correlation terms between subtypes can
be interpreted as reflecting the correlation between the subtype event rates, conditional on
the overall count in each study.
















where the conditional likelihood Li0 is defined as
Li0(yi0;µ0, vi0) = [Φ(µ0 + vi0)]
yi0 [1− Φ(µ0 + vi0)]ni−yi0 , (2.8)










]yij [1− Φ(µ∗j + v∗ij)]yi0−yij . (2.9)
We can then estimate π0 by:
π0 = E[πi0|µ0, σ0] =
∫ ∞
−∞







where Φ(·) denotes the standard normal cumulative distribution function, Z ∼ N(0, 1), and
φ(·) is the density of the standard normal distribution. Let (X,Y ) be a standard bivariate





Σ∗1,j+1. As shown in the Supplementary
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This new parameterization of the multivariate random effects model truncates the density
of each study-level subtype prevalence at the current estimate for the overall prevalence.
We hypothesized that this would decrease bias and increase precision when estimating the
population-averaged subtype prevalences.
2.3.4 Prior specifications
We use Markov chain Monte Carlo (MCMC) methods to obtain Bayesian posterior esti-
mates for each πj and Σ
∗
J+1, with N(0, 1000) priors for each µj . For the univariate models,
we put a Unif(0, 10) prior on each σj . The inverse-gamma(ε, ε), where ε is small, has pre-
viously been a popular choice of prior for σ2j , as it is conditionally conjugate [44]. However,
the results can be sensitive to the choice of ε, particularly for small σ [44]. We use the
same choice of priors with a spherical decomposition for both Σ∗J+1 and ΣJ+1. The com-
monly used conjugate inverse-Wishart prior for the precision matrix of multivariate normal
random vectors can result in inflated estimates of the variances and shrinkage of the corre-
lations towards zero, particularly when the true variances are small [29, 45]. Thus, we use
a separation strategy [46] in order to specify the priors on ΣJ+1 and Σ
∗
J+1, which involves
modeling the variance and correlation components separately. Specifically, in this case we
use the spherical decomposition described by Lu and Ades (2009) [47] and Wei and Higgens
(2013) [29] and implemented in the “pcnetmeta” R package [48], with Unif(0, π) priors on
the coordinate parameters [47].
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2.4 Missing at random (MAR) assumption
While these methods do not require that all studies measure each outcome, they do require
the assumption that the data are missing at random (MAR). That is, the probability of
an outcome being measured for any given study may depend only the observed outcomes
for that study. Since we are currently assuming that the overall outcome is observed for
all studies, when we simulate data that are MAR, we let the probability of being missing
depend only on the overall prevalence.
To illustrate, let mij = 1 if the number of events yij for the jth outcome of the ith study
is not reported. We can then model the probability that mij = 1 by:
logit (P (mij = 1)) = α0j + α1jf(πi0) + α2jg(πij), (2.12)
where f(·) and g(·) can be any functions. The specific functions we used in our simulation





j=1 P (mij = 1)
mij [1 − P (mij = 1)]1−mij . Multiplying the likelihood for the
observed data as in equation (2.5) or (2.7) with Lm, we obtain the total likelihood function
which incorporates the missing mechanism. If the data are missing completely at random
(MCAR), then α1j = α2j = 0, and the probability of the j
th outcome being missing is
some constant determined by α0j . If the data are missing at random, then α2j = 0 and the
probability of being missing only depends on the underlying event rates for the data that
are fully observed. Finally, if α2j 6= 0, then the data are missing not at random (MNAR),
since the probability of an outcome being missing depends directly on the underlying event
rate. We can evaluate the impact of the missing data assumptions by simulating patterns
of missingness that correspond to different values of α1j and α2j .
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2.5 Simulation Studies
2.5.1 Methods of simulation
In order to compare the performance of the univariate models, the standard multivariate
model, and the new multivariate model, we performed two main sets of simulations: one
with data for the two subtypes under MCAR and one under MAR. For each setting, we
simulated 2000 data sets containing 30 studies. Each data set contains the overall count
for each study (yi0), the counts for two subtypes (yi1, yi2), and the overall number of par-
ticipants in each study (ni). We let yi0 be distributed binomial with denominator ni and
success probability πi0, and yi1 and yi2 each be distributed binomial with denominator yi0







distributed as a multivariate normal with different variances. For simplicity, we let all of
the pairwise correlations be identical and equal to ρ. The overall count yi0 is observed
in all studies, while the mean probabilities of missing each subtype across all studies, m̄.1
and m̄.2 are 0.5. Each condition is repeated twice, with ni, the sample size for each study,
equal to 100 or 500. All models are fit using JAGS version 4.3.0 [49], run using R version
3.3.3 [50] and packages “rjags” [51] and “coda” [52], and consist of 2 independent chains with
20,000 samples each. We also use a burn-in period of 5,000 samples and a thinning interval
of 2. The 2,000 simulations for each condition were run in parallel using the Minnesota
Supercomputing Institute (MSI) resources.
We first simulated data for 30 studies (N = 30), where observations for the two subtypes
(yi1; yi2) were all MCAR with probability 0.5. We set the pairwise correlations between
Φ−1(πi0), Φ
−1(pi1), Φ
−1(pi2) to all be equal to ρ, which had possible values of (0, 0.4, 0.8).
The (σ0, σ1, σ2) were set to be either (0.5, 0.5, 0.5) or (0.5, 1, 1). The µ0, µ1 and µ2
are set such that the population-averaged prevalence (π0, π1, π2) were equal to (0.3, 0.15,
0.05), respectively. This corresponded to 6 different conditions, which we repeated with
ni = (100, 500) for each of the 30 studies, for a total of 12 conditions. To investigate the
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performance of proposed methods under small number of studies, we also included a set of
simulations when the number of studies N = 10 and the sample size per study ni = 100,
giving an additional 6 scenarios.
Second, we repeat each of the MCAR conditions described above, but with yi1 and yi2
under MAR and the marginal probability of being missing across all studies P (mij = 1) =
0.5 for j = 1, 2. We let the probability of missingness for the jth subtype of the ith study,
P (mij = 1) depend on πi0, the observed overall study-specific prevalence. For simplicity,
we assume P (mi1 = 1) = P (mi2 = 1), since these only depend on the overall study-specific
prevalence. From equation (2.12), we let α0j = logit(0.5), α1j = 3, j = 1, 2, and f(πi0) =
logit(πi0)− logit(π̄i0) such that P (mij = 1) is inversely proportional to the difference in the
logit of overall study-specific prevalence and its mean, i.e.,
P (mij = 1) = logit
−1(logit(0.5)− 3(logit(πi0)− logit(π̄.0)). (2.13)
Therefore, studies with smaller prevalence will be more likely to be missing, leading to ORB
as described in Section 2.1.
Finally, we also repeated each of the 6 conditions where ni = 100 for the case were
there were no missing data. This included separate cases where each data set included 30
studies or 10 studies. Overall, this corresponded to 18 MCAR and MAR conditions and 12
no missing data conditions, for a total of 48 conditions.
15
Table 2.1: (N = 30, ni = 100, MCAR) Bias, 95% credible interval width (CIW) and
coverage probability (Cov.) for univariate model, original multivariate model, and new
parameterization, across 2000 simulations containing 30 studies, where ni = 100, the true
prevalences are (0.3, 0.15, 0.05), and data are missing completely at random (MCAR).
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5), ρ = 0
Univariate 0.003 0.121 0.95 0.009 0.127 0.96 0.008 0.078 0.96
Original 0.003 0.122 0.96 0.007 0.102 0.95 0.008 0.071 0.95
New Param. 0.004 0.124 0.96 0.002 0.097 0.95 0.005 0.061 0.95
σ = (0.5, 0.5, 0.5), ρ = 0.4
Univariate 0.003 0.121 0.95 0.010 0.143 0.97 0.011 0.094 0.97
Original 0.003 0.122 0.96 0.007 0.109 0.96 0.009 0.076 0.95
New Param. 0.004 0.124 0.96 0.003 0.103 0.95 0.006 0.066 0.94
σ = (0.5, 0.5, 0.5), ρ = 0.8
Univariate 0.002 0.121 0.96 0.012 0.158 0.97 0.013 0.105 0.96
Original 0.002 0.121 0.95 0.006 0.114 0.96 0.007 0.074 0.96
New Param. 0.003 0.122 0.96 0.004 0.107 0.96 0.005 0.066 0.95
σ = (0.5, 1, 1), ρ = 0
Univariate 0.002 0.121 0.95 0.013 0.162 0.96 0.018 0.132 0.97
Original 0.003 0.123 0.96 0.012 0.146 0.95 0.021 0.133 0.95
New Param. 0.004 0.124 0.96 0.001 0.121 0.96 0.010 0.089 0.95
σ = (0.5, 1, 1), ρ = 0.4
Univariate 0.002 0.121 0.96 0.015 0.183 0.97 0.023 0.153 0.97
Original 0.003 0.123 0.96 0.012 0.152 0.96 0.022 0.137 0.95
New Param. 0.004 0.124 0.96 0.003 0.129 0.96 0.011 0.097 0.95
σ = (0.5, 1, 1), ρ = 0.8
Univariate 0.002 0.121 0.96 0.018 0.203 0.97 0.025 0.166 0.96
Original 0.002 0.121 0.96 0.010 0.148 0.96 0.018 0.123 0.96
New Param. 0.003 0.122 0.96 0.004 0.132 0.95 0.011 0.096 0.95
2.5.2 Simulation results
Table 2.1 summarizes the results where N = 100 and approximately 50% of the subtype data
are MCAR across studies. All three models gave similar results for the fully observed overall
outcome, with the univariate model having slightly less bias and shorter credible intervals
than the two multivariate models. However, using the new parameterization reduced both
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bias and 95% credible interval width (CIW) for the two subtypes under all conditions,
outperforming both the univariate and original multivariate models. This reduction in bias
and CIW for the two subtypes became larger as both ρ and the subtype variance increased.
The original multivariate model still reduced bias and CIW over the univariate approach,
except when ρ = 0, where it corresponded to a larger bias, CIW, or both. We observe
qualitatively similar results for each condition when N = 500, as well as the conditions
where each data set contained only 10 studies, which are given in Tables A.2 and A.4 in the
Supplementary Materials, respectively.
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Table 2.2: (N = 30, ni = 100, MAR) Bias, 95% credible interval width (CIW) and cov-
erage probability (Cov.) for for univariate model, original multivariate model, and new
parameterization, across 2000 simulations containing 30 studies, where ni = 100, the true
prevalences are (0.3, 0.15, 0.05), and data are missing at random (MAR).
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5), ρ = 0
Univariate 0.003 0.121 0.95 0.064 0.127 0.38 0.027 0.081 0.65
Original 0.003 0.123 0.96 0.017 0.121 0.94 0.014 0.089 0.93
New Param. 0.004 0.124 0.96 0.002 0.092 0.96 0.005 0.057 0.96
σ = (0.5, 0.5, 0.5), ρ = 0.4
Univariate 0.003 0.121 0.95 0.078 0.150 0.35 0.037 0.102 0.56
Original 0.003 0.122 0.96 0.014 0.116 0.94 0.013 0.080 0.94
New Param. 0.004 0.124 0.96 0.005 0.099 0.95 0.007 0.060 0.96
σ = (0.5, 0.5, 0.5), ρ = 0.8
Univariate 0.003 0.121 0.96 0.092 0.161 0.27 0.045 0.108 0.42
Original 0.003 0.121 0.95 0.013 0.113 0.94 0.010 0.070 0.95
New Param. 0.003 0.122 0.96 0.008 0.104 0.95 0.007 0.058 0.94
σ = (0.5, 1, 1), ρ = 0
Univariate 0.003 0.121 0.95 0.068 0.189 0.65 0.040 0.159 0.83
Original 0.004 0.124 0.96 0.032 0.195 0.95 0.038 0.185 0.93
New Param. 0.004 0.124 0.96 0.002 0.114 0.96 0.011 0.084 0.95
σ = (0.5, 1, 1), ρ = 0.4
Univariate 0.003 0.121 0.96 0.090 0.202 0.50 0.052 0.171 0.67
Original 0.004 0.123 0.96 0.025 0.172 0.95 0.029 0.152 0.93
New Param. 0.005 0.124 0.97 0.007 0.123 0.96 0.013 0.087 0.95
σ = (0.5, 1, 1), ρ = 0.8
Univariate 0.003 0.121 0.96 0.112 0.210 0.34 0.063 0.173 0.55
Original 0.003 0.121 0.96 0.016 0.141 0.93 0.016 0.104 0.95
New Param. 0.004 0.123 0.96 0.011 0.128 0.94 0.011 0.084 0.94
The reduction in bias for the two subtypes for the two multivariate parameterizations
increased when the data were MAR, as shown in Table 2.2 (N = 100) and Table A.3 (N =
500). This includes the conditions in the MCAR scenarios (where ρ = 0) where the original
multivariate model sometimes had larger bias than the univariate models for the subtype
outcomes. In the MAR case where ρ = 0, σ = (0.5, 1, 1), and N = 100, using the original
18
multivariate parameterization reduced bias by 52.9% and 5.0% for subtypes 1 and 2, respec-
tively, while using the new parameterization reduced it by 97.1% and 72.5%, respectively,
when compared to the univariate models. As expected, the coverage probabilities for the
univariate models were quite low when the data were MAR (as low as 23.4% for the N =
500, σ = (0.5, 0.5, 0.5), ρ = 0.8 scenario). We again observed similar results when N = 10
(Table A.5).
The results for the cases where there were no missing data are presented in Tables
A.6 and A.7 in the Supplementary Materials for N = 30 and N = 10, respectively. Here,
the original multivariate model provided little to no benefit over using separate univariate
models. Under many conditions, this model had larger bias and wider credible intervals on
average than the separate univariate models. We hypothesize that without any missing data,
the original multivariate model’s ability to borrow information across outcomes may not
make up for the additional model complexity. These results are also consistent with previous
literature [16, 31]. However, the new parameterization still had reduced bias and credible
interval widths even without missing data. We hypothesize that this is due to the reduction
in density where the subtypes would have greater prevalence than the overall outcome.
Furthermore, in the case where the subtype outcomes are distributed as binomial with the
denominator equal to the overall count, the probit (or logit) transformed prevalences likely
do not follow a normal distribution. This could further explain the reduction in bias found
with the new parameterization.
In summary, using the two multivariate parameterizations did not improve performance
when focusing solely on estimating the overall prevalence. However, these models improved
estimation of the prevalences of the two subtypes over using separate univariate models,
particularly under the MAR conditions, with the new parameterization outperforming the
original multivariate model under all conditions.
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2.6 The Case Study
2.6.1 Results under missing at random assumption
Table 2.3a presents estimates of the overall urinary incontinence (UI) prevalence and that of
each subtype (SUI, UUI) found using separate univariate models, the multivariate model,
and the new parameterization accounting for the subtype constraint. Each model was
fit using 3 independent chains with 250,000 samples each and a burn-in period of 5,000
samples. We used a substantially larger number of iterations for the case study in order
to generate smooth plots of the estimated density of the posterior predictive distribution.
We also report the posterior mean and standard deviation of the between study variances
and the correlations between outcomes in Table 2.3b. We expect the estimates of the
covariance matrices to differ between the two parameterizations, since the random effects
for the subtypes in the new parameterization refer to the variability in the proportion
of overall cases that fall into that subtype, rather than the variability in study specific
prevalence.
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Table 2.3: Case Study Results
Model UI CIW SUI CIW UUI CIW
Univariate 0.274 (0.024) 0.096 0.127 (0.022) 0.088 0.066 (0.021) 0.082
Multivariate 0.275 (0.025) 0.098 0.128 (0.022) 0.088 0.064 (0.019) 0.072
New Parameterization 0.275 (0.025) 0.099 0.123 (0.02) 0.078 0.061 (0.016) 0.064
(a) Posterior mean (SD) of marginal prevalences for overall outcome (UI) and two subtypes (SUI, UUI) with
corresponding 95% credible interval width (CIW)
σ̂1 σ̂2 σ̂3
Univariate 0.383 (0.060) 0.435 (0.089) 0.607 (0.131)






New Param. 0.399 (0.064) 0.755 (0.160) 0.683 (0.157)
ρ̂12 ρ̂13 ρ̂23






New Param. -0.115 (0.249) 0.364 (0.233) 0.103 (0.270)
(b) Posterior mean (SD) of components in estimated covariance matrices for original
multivariate model and new parameterization (Σ̂, Σ̂∗)
All three models gave similar results for the overall prevalence of UI. The estimates of
the SUI prevalence differed slightly across the three models, with the new parameterization
giving the smallest estimate. The proportion falling into the SUI subtype also had low
correlation with the overall outcome under the new parameterization (-0.115) and larger
variance (0.755). The 95% credible interval was wider for the original parameterization,
than the univariate model, similar to the σ = (0.5, 1, 1) and ρ = 0 scenarios from Section
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2.5.2. However, the new parameterization still reduced 95% credible interval width by 11.4%
compared to the univariate model.
The estimated marginal prevalence of UUI was highest under the univariate model, and
lowest under the new parameterization. The proportion falling into the UUI category had
a higher estimated correlation with the overall outcome under the new parameterization
(0.364) and slightly lower estimated variance (0.600) when compared to the SUI outcome.
Jointly modeling the outcomes resulted in a 12.2% and 22.0% reduction in 95% credible
interval width for the original and new multivariate parameterizations, respectively. Based
off of the original model, the estimated unconditional correlation between the SUI and
UUI subtypes was relatively low (0.395). As estimated by the new parameterization, the
estimated correlation conditional on the overall count was even smaller (0.103).
Figure 2.1 presents forest plots for each outcome, showing the shrunken estimates for
the study-level prevalences under the three different models. The estimates and credible
intervals are similar across all three methods for the overall prevalence of UI, as well for the
subtypes in studies where the given outcome is observed. While the univariate model cannot
estimate study level prevalence for unobserved subtypes, the two multivariate parameter-
izations can do so using information from the correlations and observed outcomes. The
new parameterization gave narrower credible intervals than the original multivariate model
when estimating subtype prevalence corresponding to the unobserved outcomes. Similarly,
Figure A.1 presents posterior density plots for each outcome, by model. This illustrates the
reduction in density at larger values when using the new parameterization.
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Figure 2.1: Forest Plot of Study Level Estimates Posterior mean and 95% credible interval
of marginal and study level prevalences for each of the three outcomes across 26 studies
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Figure 2.2: Bivariate Density Plots for Predicted Prevalences in New Study (a) Overall
and SUI posterior predicted prevalences for new study based on original multivariate model
results, (b) Overall and UUI with original multivariate model, (c) Overall and SUI with
new parameterization, (d) Overall and UUI with new parameterization

















































































We further investigated this reduction in joint density by the new parameterization using
the posterior predictive bivariate density plots, as shown in Figure 2.2. We estimated these
posterior predictive distributions by drawing a random sample representing the prevalences
of a future study from the joint posterior distributions of parameters at each of the 750,000
total iterations. Of the samples generated according to the results from the original mul-
tivariate model, 64 samples and 1 sample gave estimates where the overall UI prevalence
was smaller than the corresponding estimates for the SUI and UUI prevalences, respectively.
The new parameterization on the other hand specifically prevents this from occurring, which
explains the reduction in density between (a) and (c) in Figure 2.2. Finally, we tested the
sensitivity to the choice of the separation strategy prior on the covariance matrix by rerun-
ning the two multivariate models using an inverse-Wishart prior. The results are included in
Table A.8 in the Supplementary Materials, and are similar to those found using the previous
choice of prior.
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Figure 2.3: Sensitivity Analysis Posterior mean and 95% credible intervals for UI, SUI, and
UUI marginal prevalence across values of α2
UI SUI UUI






















2.6.2 Sensitivity analysis results under MNAR
When fitting each model, we assume that the probability of each study missing a subtype
outcome does not directly depend on the underlying prevalence. As we cannot directly test
whether the data are MNAR, we conduct a sensitivity analysis assuming several different
patterns of missingness to evaluate the impact of different degrees of MAR violations. We
assume that mij ∼ Ber(qij), where qij is the probability of subtype j for study i being
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missing. Specifically, we specify a logistic model for qij as logit (qij) = α0j + α2jπij , where
α2j is not identifiable. Instead, we specify values for α2j ∈ [−2, 2], with increments of 0.1
and observe how the estimates of the marginal prevalences π0, π1, π2 vary when (2.12) is
incorporated into the likelihoods for the original multivariate model (2.5) and new param-
eterization (2.7). For simplicity, we let α21 = α22 = α2 for each α2j ∈ [−2, 2].
Figure 2.3 presents the posterior means and 95% credible intervals of π0, π1, and π2 for
the two models under each value of α2 ∈ [−2, 2]. As expected, the posterior mean for the
overall UI prevalence (π0) remained approximately constant across values of α2, since it
is fully observed. However, the posterior means for the two subtype prevalences (π1, π2)
generally increased with α2. Larger values of α2 corresponded to studies with larger πij
missing with higher probability, thus the estimated prevalence became larger in order to
incorporate this fact. The posterior mean of π1 ranged from (0.123, 0.133) and from (0.120,
0.126) for the original and new parameterizations, respectively, while the posterior mean
of π2 ranges from (0.061, 0.067) and from (0.059, 0.064). Therefore, violating the MAR
assumption to this extent led to a slightly larger difference in estimates for the original
model than for the new parameterization. We also note that the upper limit of the 95%
credible interval from the new parameterization is consistently lower than that from the
original model for the SUI and UUI panels of Figure 2.3.
In general, the mechanism of MNAR is unobservable. The sensitivity analysis above
was intended to examine the risk of bias under a few MNAR mechanisms. Missingness may
depend on other unobserved characteristics of the study population and even if missingness
is only related to subtype prevalences, the dependency may differ from what we considered.
2.7 Discussion
Jointly modeling the overall and each subtype prevalence using multivariate random effects
models generally improved both bias and precision for the marginal subtype estimates by
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“borrowing strength” across outcomes. Incorporating the natural subtype constraint im-
proved estimation further, likely by eliminating density in regions where the subtype preva-
lence would be larger than the overall prevalence for an individual study. This occurred
even under the few conditions where the original multivariate parameterization failed to im-
prove estimation, including when there were no missing data. Using the original multivariate
model was the least beneficial when correlations between outcomes were low, variances were
large, and the data were MCAR. We hypothesize that the multivariate models cannot bor-
row much information when ρ = 0. In this case, the multivariate model required estimating
far more parameters than the univariate models, thus increasing variability. However, the
new parameterization improved estimation under these conditions by taking into account
the natural constraint in the data. Both models improved bias when the data were MAR
and correlations were large, with the new parameterization still outperforming the original
multivariate model.
This behavior was reflected in the results of the case study. The SUI subtype had low
correlation with the overall outcome under the new parameterization and slightly larger
variance. This likely led to the original multivariate model giving a wider 95% credible in-
terval than the univariate model, while the new parameterization having a slightly narrower
credible interval. The UUI subtype had a slightly higher correlation with the overall out-
come and slightly lower variance. In this case, the original multivariate model had a slightly
shorter 95% credible interval than the univariate model, consistent with the results of the
simulations. We were also able to directly observe the reduction in density in the posterior
predictive distributions for a single study associated with using the new parameterization,
as shown in Figure 2.2. Finally, using the original and new multivariate parameterizations
to jointly model the case study outcomes allowed us to estimate the correlation between
subtypes both unconditionally and conditioned on the overall outcome.
Because the simulation conditions were generated under the new parameterization in or-
der to ensure the subtype counts did not exceed the overall counts, the correlations used to
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generate the data correspond to the overall outcome and proportions falling into each sub-
type. Large positive or negative correlations between the two subtypes would imply that
the subtypes had a high co-morbidity or tended toward mutual exclusivity, respectively.
Therefore, we hypothesize that using the new parameterization would be the most advanta-
geous when a disease or set of outcomes are suspected to have either of these characteristics.
However, if the subtypes were known to be mutually exclusive, a multinomial model would
be more appropriate. We also caution that the methods may not be appropriate in the case
of very rare diseases, resulting in very sparse counts, as the resulting estimates may not be
stable.
Because we based the simulated marginal prevalences on those observed in the case
study, all simulations were conducted using (π0, π1, π2) = (0.3, 0.15, 0.05). Therefore, the
elimination of density by the new parameterization excluded all values above approximately
0.3, omitting about 70% of the original space. Furthermore, we hypothesize that this
reduction in density may have the most impact in cases where at least one subtype has a high
prevalence relative to the overall outcome. In this situation, the original multivariate model
would likely have a greater number of samples where the subtype prevalence estimate was
incorrectly higher than the overall prevalence. While we assume in this paper that the overall
outcome is fully observed, these methods could be used when some studies do not report the
overall count, such as in the food allergy [13] and autism spectrum disorder (ASD) [14] meta-
analyses mentioned in Section 2.1. While both multivariate methods can be implemented
with multiple subtypes, the estimates may become unstable in higher dimensions depending
on the amount of missing data, variances, and correlations between outcomes. More work
would be needed to evaluate these models’ performance in higher dimensional scenarios.
As mentioned in Section 2.12, both multivariate methods require that any missing data
be MAR or MCAR. Our analysis of the case study data included a sensitivity analysis of
a specific MNAR mechanism, but the true missingness mechanism remains unknowable.
However, we hypothesize that it may be less common for the type of prevalence data we
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have described to be MNAR. If the data were MNAR, the probability of a given subtype
being missing would directly depend on the underlying prevalence of each study. One
such scenario would be given by investigators choosing not to report the prevalence of a
subtype with a low count. We view this as unlikely, since if a study aiming to estimate
the prevalence of a subtype encountered a lower frequency than expected, the outcome
would still be of interest. Furthermore, while we have described in Section 2.1 the possible
situation of studies measuring a lower overall prevalence being less likely to measure the
lower frequency subtypes, this would be a case of the data being MAR, as the probability
of being missing would depend on the overall count.
As discussed in Section 2.3.4, we use the separation strategy initially proposed by
Barnard et al. (2000) [46] for the priors on the covariance matrices in the two multivariate
models. The separation strategy has been shown to improve estimation of the variance and
covariance terms over the use of an inverse-Wishart conjugate prior by adding more flexi-
bility. However, this method also greatly increased computational time, as the multivariate
models took up to a few hours to fit, depending on the number of iterations used. Using an
HMC sampler such as STAN may decrease computational time over JAGS (a Gibbs based
sampler) [45].
To the best of our knowledge, there is only one other existing multivariate meta-analysis
of multivariate prevalence data [10]. This serves as a case study illustrating the potential
improvement in estimation by jointly modeling multivariate prevalence data, particularly
when incorporating additional natural constraints into the model parameterization. The
methods used in this analysis allowed us to better compare prevalence rates of specific
lower urinary tract symptom types across different occupation types in working women.
These comparisons have informed future research on a wider range of lower urinary tract
symptoms, in addition to urinary incontinence.
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Chapter 3
Estimating the Reference Range from a
Meta-Analysis
3.1 Introduction
The number of published meta-analyses has increased sharply over the past several decades
[1, 37]. While most meta-analyses aim to provide a more precise estimate of the effect of a
treatment or a risk factor’s association with a disease [1], the literature has many examples
of meta-analyses of normative data [7–9,12,53–59]. These studies generally aim to establish
“typical” or “normal” values for a measurement or outcome using “healthy” populations
from multiple studies, to serve as a reference. However, most often these meta-analysis
studies report the pooled mean as the “reference value,” which has limited interpretability
when determining whether a measurement is “normal”. Although Bohannon [53] noted that
measurements lying outside the confidence interval for the pooled mean could be considered
above or below “average”, a reference range would be more useful in determining whether
an observed measurement was within the range of values measured on healthy individuals.
Horn et al. [21] define a reference range or interval as “a set of values within which some
percentage, 95% for example, of the values of a particular analyte in a healthy population
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would fall.” In a meta-analysis, this requires accounting for the natural variability in the
healthy population as reflected by variation both within and between studies.
Several medical systematic reviews have estimated and reported reference ranges using
a meta-analysis of healthy individuals from multiple studies [7, 9, 56, 58, 60–63]. However,
some of these studies have used the confidence interval for the pooled mean as the “reference
range” [7,61,62], which reflects uncertainty in the estimated mean, not natural variation in
the population. Venner et al. [63] used the measurement ranges reported in each study when
available to construct reference ranges based on the overall minimum and maximum values
across studies. While this better reflects natural variation across healthy individuals than
the confidence interval for the pooled mean, only four out of the twelve studies included in
the meta-analysis reported ranges, and this method requires setting the desired percentage
of individuals captured in the reference range to 100%.
However, several studies estimate reference ranges containing a specified proportion of
measurements from a healthy target population based on the observed mean, standard de-
viation, and sample size from each study [9, 56, 58, 60]. Conceição et al. [9] use a method
similar to the empirical approach proposed later in this paper in order to estimate normal
ranges for how accurately healthy participants perceive whether they are oriented verti-
cally in space. Wyman et al. [58] use the fixed effects model by Laird and Mosteller [64]
in order to establish normative ranges for non-invasive bladder function measurements in
healthy women. Németh et al. [56] estimate a reference range for normal concentrations of
asymmetric dimethylarginine in the plasma of healthy individuals, though their method for
estimating the marginal reference range across all studies is not clear. Finally, Khoshdel et
al. [60] simulate individual patient data based on the summary statistics from each study,
then use fractional polynomials to estimate age-specific reference ranges for pulse wave
velocity.
It is unknown what proportion of measurements from the“true”overall populations these
reference ranges capture. Currently, the literature gives no guidance on how to approach
32
the question of estimating reference ranges based on meta-analyses. Several authors have
recently advocated reporting prediction intervals for a new study [65–68], but they have not
addressed prediction for an individual. To the best of our knowledge, the present paper is
the first to propose methods for estimating reference ranges based on meta-analyses.
The first two proposed methods build on the commonly used random effects model.
Section 3.2 motivates this choice and introduces notation. Section 3.3 proposes three ap-
proaches for estimating reference ranges. The first uses results from a frequentist method
such as restricted maximum likelihood estimation (REML), while the second is a Bayesian
approach using a posterior predictive interval. The final method is an empirical approach
similar to that used by Conceição et al. [9]. We call these the frequentist, Bayesian, and
empirical approaches. All three of these approaches use the means, standard deviations,
and sample sizes reported in each study and do not require individual patient data. Section
3.4 presents simulation studies illustrating the performance of the three approaches, which
we then apply to two examples in Section 3.5. Finally, Section 3.6 discusses some of the
key distributional assumptions required by these approaches and potential areas of future
work.
3.2 Random effects model
3.2.1 Choice of model
Three models are commonly used in meta-analysis: the common effect, random effects, and
fixed effects models. The common effect model assumes the underlying true mean or effect
is the same in each study and that variation between studies in estimated mean arises purely
from sampling variation [69, 70]. This is often called a fixed effect model, which is easily
confused with the fixed effects model of Laird and Mosteller [64]. We follow Bender et al. [69]
by using the term “common effect model”. This model imposes a strong assumption that
each study population has the same underlying true mean, which may not be appropriate
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for situations in which the observed means from the studies differ for reasons other than
sampling variability [71]. When there is considerable heterogeneity between studies, as is
often the case in meta-analyses of continuous outcomes [72], it may instead be desirable to
assume that each study has a different true mean and that these means are drawn from
separate distributions, as in the fixed effects model of Laird and Mosteller [64]. However,
because this model makes no assumptions about how the effects in the different studies
are related, it may not be used to draw any conclusions about a new study measuring
the same outcome, much less about a new individual. Therefore, we will instead focus
on the random effects model. This model allows the true means to differ between study
populations but assumes they follow some underlying distribution, which is most often a
normal distribution [69, 70]. It is common to interpret this assumption as meaning that
each study in the meta-analysis was randomly sampled from a population of theoretically
possible studies, including the population studied and methods of measurement. However,
Higgins et al. [73] point out that this stronger assumption is often violated, as later studies
are often designed based on the results of previous studies. However, Higgins et al. [73]
focus on random effects models comparing treatment effects in two groups, while we focus
on estimating normal ranges from a group of healthy subjects. Thus, this assumption may
be reasonable.
3.2.2 Notation
Let ȳi denote the observed mean for study i = {1, ..., N}, θi be study i’s true mean, µRE
be the overall mean of the distribution of study means, and σ2i be study i’s within-study
variance. Also, let τ2 be the variance of the θi across studies. Then, we have
ȳi ∼ N(θi, σ2i /ni), θi ∼ N(µRE , τ2) (3.1)
In the frequentist framework, the overall mean µRE is traditionally estimated as a
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, for wi,RE =
1
s2i /ni + τ̂
2
, (3.2)
where s2i is study i’s within-study sample variance though there has been some debate about
how to estimate τ2. Here, we use the restricted maximum likelihood (REML) estimate, as
implemented in the “meta” package [75]. The commonly-used estimate originally proposed
by DerSimonian and Laird [74] has been shown to underestimate the true between-study
variance, particularly when the number of studies k is small [76–78]. The overall variance in
µ̂RE can be estimated by VRE =
1∑k
i=1 wi,RE
. The following is commonly used as an α-level
confidence interval for µ̂RE : µ̂RE ± zα/2×
√
VRE , where zα/2 is the standard normal critical
value for the chosen significance level (α).
Alternatively, one can take a Bayesian approach and place prior distributions on µRE
and τ as described in Section 3.3.2 [41,73]. Because we consider the fixed mean assumption
in the common effect model inappropriate in most situations, we use a random effects model
for the two model-based approaches presented below. However, one could easily alter these
methods to reflect a common effect assumption.
3.3 Methods for estimating the reference range from a meta-analysis
In estimating a 95% normal reference range, we aim to find an interval that contains approx-
imately 95% of individuals in the target population [79, 80]. Because the models described
in Section 3.2 only allow inference on the pooled mean, we need additional methods and
assumptions to estimate the 95% normal reference range for an individual. First, we must
make an assumption about the distribution of the data within each study, assuming we do
not have access to the study’s individual patient data (IPD). In this paper, we assume the
individual-patient data in each study were generated from either a normal or log-normal
distribution, with the family of distribution being consistent across all studies. We present
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three approaches to estimating the normal reference range: a frequentist approach, a fully
Bayesian approach, and an empirical approach. The frequentist and Bayesian methods
assume the within-study distributions have the same variance in all studies, while the em-
pirical approach does not. We present each of our three proposed methods under normality,
and then show how to apply them under a log-normality assumption.
3.3.1 A frequentist approach
Under the random effects model, if we assume observations within each study are normally
distributed, the within-study variances are the same in all studies, and the study-specific
means follow a normal distribution, then we have yij ∼ N(µRE , σ2T ), where σ2T = τ2 + σ2
and σ2 is the common within-study variance. We can estimate µ̂RE and τ̂ as described in






Substituting µ̂RE , τ̂
2, and σ̂2 into the marginal distribution of yij , the marginal distribu-
tion of individuals, marginal to studies, can be estimated asN(µ̂RE , σ̂
2




The α/2 and 1−α/2 percentiles of this distribution can then be taken as the bounds of the
α-level normal reference range: µ̂RE ± z1−α/2
√
σ̂2 + τ̂2. Because σ̂2 and τ̂2 were estimated,
this suggests that a t-distribution may be appropriate instead of a normal. However, most
meta-analyses will have a large enough total sample size across studies that the appropriate
t-distribution will be closely approximated by a normal distribution. Alternatively, the fully
Bayesian method presented in Section 3.3.2 accounts for the uncertainty in σ̂2 and τ̂2.
3.3.2 A Bayesian approach
A fully Bayesian approach places prior distributions on µRE and τ . As in the frequentist
approach, we assume that the true variances are the same in all studies, and now we use the
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normal-theory sampling distribution of the sample variance to capture uncertainty about
the within-study variance σ2, according to this model:
ȳi ∼ N(θi, σ2/ni)
θi ∼ N(µRE , τ2)










We place a N(0,1000) prior on µRE and Unif(0,100) priors on τ and σ, then sample from
the posterior predictive distribution for a new individual to incorporate into the normal
reference range uncertainty about each of the parameter estimates:
ynew ∼ N(µRE , σ2 + τ2), (3.5)
where the predictive density of ynew given the data {yij} is given by:
f(ynew|{yij}) =
∫ ∫ ∫
f(ynew|µRE , σ2, τ2)f(µRE , σ2, τ2|{yij})dµREdσ2dτ2 (3.6)
The limits of the α-level normal reference range can then be estimated by the α/2 and
1− α/2 percentiles of ynew’s predictive distribution.
3.3.3 An empirical approach
The third approach is a simple empirical approach that does not assume the studies all
have the same within-study variances and does not specify the distribution of yij within
each study. However, like the frequentist approach in Section 3.3.1, it does not account
for estimation uncertainty and assumes the population captured across all studies follows a








This is equivalent to the pooled mean in Laird and Mosteller’s [64]’s fixed effects model,
weighted by sample size. Then estimate the marginal variance across studies using the







i=1(ni − 1)(ȳi − µ̂)2∑N
i=1(ni − 1)
(3.8)
The limits of the α-level normal reference range are then given by the α/2 and (1−α/2)
percentiles of a N(µ̂emp, σ̂
2
T,emp) distribution: µ̂emp ± z1−α/2 × σ̂T,emp. Conceição et al. [9]
used this method but weighted by n rather than n−1 in the variance calculation. We prefer
the unbiased estimate of the variance, but weighting by n will generally give similar results.
3.3.4 Lognormal distribution for yij
Each of the above methods can also be applied when each study’s observations are assumed
to be drawn from a lognormal(θi, σ
2
i ) distribution, so that log(yij) ∼ N(θi, σ2i ). In this
case, first transform the observed study means and sample variances to the log scale using

















This transformation uses the method of moments estimators for the location and scale
parameters of the lognormal distribution. For more details, see the Appendix. The normal
reference range can then be estimated as before, substituting ȳ∗i and s
∗
i for the observed
study-level means and standard deviations. Finally, exponentiate the limits of the resulting




. This method requires
that the ȳ∗i ’s be normally distributed, an assumption that should be checked using a method
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such as a Q-Q plot. Depending on the distribution of ȳi, the distribution of the ȳ
∗
i ’s can be
quite skewed.
3.4 Simulations
3.4.1 Methods of simulation
To assess how well each of the three methods captures a true 95% normal reference range, we
conducted simulations under a variety of different conditions. In all conditions, we assumed
the true distributions within studies were normal and that the true study-specific means
varied according to the random effects model in Section 3.2. For each condition, we then
considered different values of true between-study variation (τ2) as a proportion of total
variability (τ2 + σ2). In all conditions, each study had 50 subjects, with the total number
of studies (N) being 5, 10, 20, or 30. The overall pooled mean (µ) was set to 8 and the true
total variance (σ2 + τ2) was 1.25 for all conditions. We conducted 1000 simulations for each
condition. We considered scenarios where the true study-level variances were equal, as well
as cases where they were not equal. For the frequentist approach, we used the R package
“metagen” [81] to fit the random effects model using REML. For the Bayesian approach,
we used JAGS version 4.3.0 with the packages “rjags” [51] and “coda” [52], in R version
3.6.0 [82]. We ran two chains each with 10,000 samples and after discarding 1,000 samples
for burn-in.
Equal variances
For the equal variance scenario, we first generated the true study-level means (θi’s) according
to a N(µ, τ2) distribution. For each study i, we then generated the individual-level data
according to a N(θi, σ
2) distribution, where σ2 was constant across studies. We summarized
the means and standard deviations for each study to give the observed summary data, fit
each of the three models, frequentist, Bayesian, and empirical, then found the area under
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the probability density function of a N(µ, σ2 +τ2) distribution between the upper and lower
limits of the estimated 95% normal reference ranges.
Unequal variances
Data were simulated in the unequal variance scenario as in the equal variance scenario except
that we generated σi, the true within-study standard deviation, from a doubly-truncated
normal distribution, with both the left truncation point and mean equal to X and the
right truncation point equal to X + 1, for X ranging from 0 to 0.64, with increments of
0.02. For each X, we estimated E[σ2i ] by simulating from the doubly-truncated normal
distribution. These estimates ranged from 0.291 to 1.246. We let τ2 = 1.25− Ê[σ2i ] so as X
increased, Ê[σ2i ] increased as a proportion of the total variance. Because we truncated the
normal distribution, the variance of σi remained constant throughout all conditions. We
approximated the true reference distribution for yij by simulating from the full conditional
distributions: σi|X, θi|µ, σi, and yij |θi, σi, τ .
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Figure 3.1: Simulation Results, Equal Variances. Median, 2.5th percentile, and 97.5th
percentile of the proportion of the true population distribution captured by the estimated
95% reference range, for different numbers N of studies. The horizontal axis is τ2 as a
proportion of the total variance.
Frequentist Bayesian Empirical



















We first generated the data under the equal within-study variance scenario and measured
the fraction of the true population distribution captured by each of the three reference
41
range methods, which we call the “coverage” (Figure 1). For example, when the between
study variance comprised 25% of the overall variance, the frequentist reference ranges based
on 1000 simulated meta-analyses containing 30 studies captured a median of 94.9% of a
N(µ, σ2+τ2) distribution, the true distribution of individual measurements. This can also be
interpreted as the frequentist reference ranges excluding a median of 5.1% of extreme values.
The observed median and variability of coverage depended on the true ratio of between-
study variance (τ2) to total variance (τ2 +σ2) and the number of studies N included in the
meta-analysis. For the frequentist and empirical methods, the median coverage decreased
as τ2 increased as a fraction of the total variance; this decrease was most pronounced
when the number of studies included was small (N = 5 or 10). In these conditions, the
empirical method’s coverage decreased more quickly than the frequentist method’s. Also,
variation in coverage increased as τ2 increased and decreased as N increased. While the
variation in coverage also increased with τ2 for the Bayesian posterior predictive interval,
this effect was less dramatic. In contrast with the frequentist and empirical methods, the
Bayesian method’s median coverage increased with τ2. This increase began for smaller τ2
and was more extreme for small N . This increase in variation with τ2 appears to reflect the
additional estimation uncertainty when τ2 is large, particularly when N is small. Unlike the
frequentist and empirical methods, the Bayesian method accounts for posterior uncertainty
about each parameter and thus appears more conservative. The results for the unequal
within-study variances case were qualitatively similar to the equal variance case (Figure
3.2).
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Figure 3.2: Simulation Results, Unequal Variances. Median, 2.5th percentile, and 97.5th
percentile of the proportion of the true population distribution captured by the estimated
95% reference range, for different numbers N of studies. The horizontal axis is τ2 as a
proportion of the total variance.
Frequentist Bayesian Empirical




















3.5.1 Example 1: Pediatric Nighttime Sleep
Galland et al. [12] sought to establish “reference values” for pediatric nighttime sleep out-
comes measured by actigraphy, based on a systematic review and subsequent meta-analysis
of 79 studies. We focus on the outcome wake after sleep onset (WASO) time in hours. The
authors found 24 studies reporting WASO, with most participants belonging to the same
age group (9-11 years) so they focused on the pooled mean across all age groups. In our
review of these studies, one study included in this meta-analysis [83] did not appear to
actually report WASO but rather reported the average length of wake bouts. We excluded
this study from our analysis, which therefore contained 23 studies. Figure 3.3 shows the
pooled mean and corresponding standard errors. In this case, only one of the 95% confi-
dence intervals for the study means overlapped with the point estimate of the pooled mean.
Galland et al. [12] explain that this variability reflects inconsistency across studies in how
waking bouts were defined as well as a low specificity when using actigraphy to identify
wakefulness. The authors also used meta-regression to investigate regional differences in
sleep as a source of variation but did not observe a difference across study regions. This
large variation in estimated WASO time across studies provides further evidence that the
pooled mean may not provide a full picture of what constitutes a “normal” WASO time and
that a reference range may be more useful. To better visualize the heterogeneity in WASO
time within and across studies, we also present frequentist 95% prediction intervals based
on a t-distribution for each study in the same figure [65, 66]. Because Galland et al. [12]
only reported study means and standard errors, we obtained the standard deviations di-
rectly from each study’s paper. When the paper did not report the standard deviation, we
estimated the standard deviation using the standard error reported by Galland et al. [12]
and a normal approximation. Therefore, our results should be interpreted as merely an
illustration of the proposed methods.
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Figure 3.3: WASO Mean (95% CI) and 95% predictive interval for a new individual for
each study, overall estimate of pooled mean (95% CI) based on REML , 95% predictive






































We checked whether the study means deviated from normality using a QQ-plot (see
Supplementary Materials); no apparent departure from normality is observed except a few
points at the end of both tails. As in the simulations, we used the R package “metagen” [81]
to fit the random effects model using REML. We also used this to estimate the pooled mean
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across studies and to obtain the prediction interval for a new study [73]. For the Bayesian
approach, we again used JAGS version 4.3.0 with the packages “rjags” [51] and “coda” [52],
in R version 3.6.0 [82]. We ran two chains each with 50,000 samples and after discarding
5,000 samples for burn-in. Convergence was assessed using MCMC standard error and
visual inspection of trace plots.
The estimated 95% normal reference ranges were (-0.47, 2.24), (-0.54, 2.32), and (-0.33,
2.34) for the frequentist, Bayesian, and empirical methods, respectively. We truncated these
at zero because negative WASO values are meaningless, giving (0, 2.25), (0, 2.32), and (0,
2.34). Based on the frequentist result, we would expect about 95% of healthy children to
have WASO time between 0 and 2.25 hours based on actigraphy. This reflects the large
amount of variability between individuals included in the meta-analysis. Before truncation,
the Bayesian reference range was widest, followed by the frequentist reference range; the
empirical method gave the narrowest interval. This is consistent with simulation results and
is likely due to the Bayesian method accounting for uncertainty about the parameters σ, τ ,
and µ. The code and results for both case study examples are included in the Supplementary
Materials.
3.5.2 Example 2: Frontal SPV
Accurate perception of verticality is an important part of everyday functioning and can be
altered in individuals such as “aged people, patients with vestibular disorders, Parkinson’s
disease, idiopathic scoliosis, and stroke patients” [9]. Accurate perception of verticality has
also been associated with better functioning in patients following a stroke [84]. A person’s
subjective postural vertical (SPV) can be measured by placing them in a tilting chair while
blindfolded and asking them to tell an examiner how to adjust the chair so they perceive
that they are in an upright position. Frontal and sagittal SPV refer to deviation (in degrees)
of the specified position from true verticality in the frontal and sagittal planes. Because SPV
measurements can be used to assess neurological functioning, it is important to establish a
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reference range in healthy persons.
In their meta-analysis, Conceição et al. [9] sought to establish reference ranges for frontal
and sagittal SPV from 15 studies measuring frontal SPV and 5 studies measuring sagittal
SPV. They estimated the reference range using the empirical approach except that they
weighted by n rather than n − 1 in the variance calculation. We re-analyze the data for
frontal SPV using REML to estimate the pooled mean across all studies and the 95%
predictive interval for a new study. We then used the same methods as in Section 3.5.1 to
estimate the three reference ranges.
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Figure 3.4: Frontal SPV Mean (95% CI) and 95% predictive interval for a new individual
for each study, overall estimate of pooled mean (95% CI) based on REML , 95% predictive
interval for a new study mean, and 95% reference ranges based on Bayesian, empirical, and
frequentist methods.
Anastasopoulos et al. 1997a
Anastasopoulos et al. 1997b 
Anastasopoulos et al. 1999 
Aoki et al. 1999
Bisdorff et al. 1996a 
Bisdorff et al. 1996b
Fukada et al., 2017a
Fukada et al., 2017b
Israël et al. 2012 
Joassin et al. 2010 
Mansfield et al. 2015 
Mazibrada et al. 2008 
Pérennou et al. 1998 
Pérennou et al. 2008 
Saeys et al. 2010 
Overall (REML)
95% Reference Range











We again checked for non-normality of the study-means using a Q-Q plot (see Supple-
mentary Materials); no apparent departure from normality is observed except a few points at
the upper tail. Figure 3.4 presents the reference range results as well as the estimated pooled
mean and predictive interval for a new study. Conceição et al. [9] estimated the frontal SPV
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reference range as (−2.87◦, 3.11◦). The frequentist, Bayesian, and empirical methods gave
estimated reference ranges (−2.92◦, 3.15◦), (−3.07◦, 3.20◦), and (−2.89◦, 3.13◦), respectively.
As expected, the empirical method’s results are quite similar to those reported by Conceição
et al. [9], while the frequentist and Bayesian methods give slightly wider intervals.
3.6 Discussion
This paper proposes three methods of estimating reference ranges for an individual from
a meta-analysis. The methods are simple to implement and can serve as a starting point
for future development. Based on the simulations, all three methods tended to perform
best when the number of studies was large and between-study variability was relatively
small. However, while the frequentist and empirical methods tended to underestimate the
width of the reference range as between-study heterogeneity increased (particularly for small
N), the Bayesian posterior predictive interval did not. This is likely because the Bayesian
method accounts for estimation uncertainty about the parameters, while the other methods
do not. Instead, the posterior predictive interval more often overestimated the width of the
interval. Depending on how the reference range is used, one might consider this behavior
conservative. We recommend using caution when the number of studies is small, such as
5 or 10. If the number of studies is very small and the estimated between-study variation
makes up more than 50% of total estimated variation, it may be more useful to report
reference ranges specific to each study, rather than a pooled range.
As for which method might be most appropriate in which circumstance, the simulation
results suggest that when the number of studies is large (at least 20), and the normality
assumptions hold, the three methods will likely perform similarly. Conceição et al. [9]
used the empirical approach but weighted by n instead of n − 1. This suggests that the
calculations required are intuitive and could easily be implemented by clinicians. The
frequentist method, by contrast, requires familiarity with random effects models, although
investigators are often interested in the pooled mean and thus likely to use this approach
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anyway. Finally, the Bayesian predictive interval requires familiarity with Bayesian methods
and a software such as JAGS, though it is still a simple model to implement and can account
for estimation uncertainty.
Each method makes distributional assumptions beyond those needed when estimating
the pooled mean. Besides the usual assumption made when using likelihood methods to
analyze random effects models — that the study-means are normally distributed — the
frequentist and Bayesian approaches also assume a normal distribution for individuals within
a study. While this may appear problematic, prediction intervals for a new observation based
on a single study regularly impose this assumption [85]. Unfortunately, if only study means
and standard deviations are available, this assumption cannot be validated. Section 3.3.4
extended our approaches to allow individuals within studies to be lognormally distributed,
but we caution that the transformed means on the log scale must be approximately normally
distributed. This paper focuses on meta-analyses in which individual participant data (IPD)
are not available; when IPD are available, non-parametric approaches using order statistics
may be possible, as they are currently used in non-parametric estimates of reference ranges
based on single studies [20,21].
Another key assumption of the frequentist and Bayesian methods is that the true within-
study variances are the same in all studies and that any observed differences are due to
sampling variability. Differences between studies in sampling methods or measurement
techniques could render this assumption invalid. However, Section 3.4.2’s simulation re-
sults suggest that these methods may be robust to deviations from this assumption when
the true study-specific standard deviations vary between studies according to a truncated
normal distribution. Further work is needed to assess the models’ performance under other
deviations from this assumption.
Finally, we reiterate that random effects models for estimating the pooled mean, on
which we built the frequentist and Bayesian methods, require the study-specific means
to be normally distributed. This is true of most random effects methods, except for the
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method of moments estimator developed by DerSimonian and Laird [74], which is known
to underestimate between-study variability and therefore give results with inappropriately
high precision [76–78]. It is a common misconception that normality of the study means is
guaranteed by the central limit theorem (CLT) [68]. At best, the CLT only ensures that the
sampling distribution of an observed average for a single study has an approximate normal
distribution, not that the true means of the collected studies follow a normal distribution.
One way of assessing departures from this assumption is the use of a normal Q-Q plot.
Although our methods make specific distributional assumptions, they do provide a start-
ing point for additional development. Future work should generalize these methods to ad-
dress instances where the assumptions used here are likely not met. This could involve cases
with or without IPD. Section 3.4.2’s simulation results show that our approaches work well in
cases with many studies and relatively low between-study variability. However, future stud-
ies should compare these methods with new methods incorporating IPD. Future methods
should also improve performance when the number of studies is small or the between-study
variation is large. The proposed methods may also be extended to cases where the data from
each study are assumed to follow truncated normal distributions. Finally, these methods
could be extended to a meta-regression setting to include characteristics such as age or sex,
at either the individual or the study level.
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Chapter 4
A Guide to Estimating the Reference
Range from a Meta-Analysis Using
Aggregate or Individual Participant
Data
4.1 Clinical Scenario
A 50-year-old healthy man without significant past medical history presents to his primary
care physician for a preventive health exam. He is concerned because his sister was diagnosed
with “liver fibrosis”. Although the patient has normal liver transaminases, INR, platelets,
and albumin levels, he has been overweight his entire life and drank alcohol heavily during
his college days. A liver biopsy, which is the gold standard diagnostic tool, is too invasive and
costly to be performed on a healthy asymptomatic individual. A noninvasive ultrasound-
based test called transient elastography was introduced in 2003. However, the normal range
for this test is not known and has been reported from several heterogeneous studies of
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patients with various races, ethnicities, and other demographic characteristics. Bazerbachi
et al. [7] conducted a systematic review and meta-analysis of these studies measuring liver
stiffness in healthy adults where individual participant data were available. The authors
estimated the mean stiffness in healthy non-obese individuals and reported the confidence
interval for the mean as the reference range, despite this interval reflecting only uncertainty
in the pooled mean rather than the variation across individuals. We revisit their analysis
in order to construct a reference range that incorporates natural variability across healthy
individuals in addition to the uncertainty in the estimated mean.
4.2 Introduction
Often clinicians would like to know whether a patient’s measurement falls within some “nor-
mal” range for healthy individuals. While meta-analysis most frequently involves summariz-
ing one or more treatment effects on an outcome, there are many examples of meta-analyses
of normative data [7–9,12,54,56,58,60–63,86,87]. Normative data are assumed to be drawn
from a predefined healthy population (e.g., with certain inclusion and exclusion criteria)
that can serve as a reference for future comparison [15]. Therefore, these studies aim to
establish “normal” values for continuous measurements using data from healthy individuals
across multiple studies. These data may be drawn from normative studies of healthy in-
dividuals, cohort studies, the control arms of case-control studies, or baseline values from
randomized-controlled trials in healthy populations [7, 9, 12]. In most cases, a reference
range, or an interval in which we would expect the measurements of a specified proportion
of a healthy population (e.g., 95%) to fall [20, 21], would provide the most information in
determining whether a patient’s measurement is “normal.” This can also be defined as a
prediction interval for the value of a new healthy individual conditional on the normative
data from existing evidence [21]. While several studies in the biomedical literature have
used ad-hoc methods to report reference ranges estimated from meta-analyses consistent
with this definition [9, 56, 58, 60], we have recently proposed three methods for estimating
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the reference range from a meta-analysis with aggregated data [88]. Here to provide some
practical guidance, we describe how to calculate the reference range from a meta-analysis
and outline how it differs from the confidence interval for the pooled mean and the pre-
diction interval for the mean of a new study [67, 73]. We provide an overview of the three
methods and apply them to a systematic review and meta-analysis of studies measuring
normative liver stiffness in adults. We consider using aggregate data from publications, but
also extend this to using individual participant data.
4.3 What aggregate data are typically available and needed for a
reference range meta-analysis?
Often, when conducting a meta-analysis of multiple studies to estimate the reference range,
only aggregate data are available from published studies. The required aggregate data
typically include the observed means, standard deviations, and sample sizes from each
study. Studies may also report demographic information, such as the proportion of males
and females, or the mean age of participants in the study.
4.4 Defining the population of interest
To determine whether the studies included in a meta-analysis have enrolled participants who
belong to the pre-specified target population for which a reference range is being sought,
we suggest evaluating two sources of information. The first is the inclusion and exclusion
criteria of the meta-analysis. The second is the observed demographic information provided
in the manuscripts of included studies (e.g., mean age, proportion of males or females).
Based on these two sources of data a judgment needs to be made about whether the studies
include representative participants from the target population whose reference range is being
sought. It is also important to consider whether some studies have enrolled participants with
occult disease and exclude such studies. For example, healthy volunteers who have occult
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fatty liver disease and enroll in hepatology studies is a well recognized phenomenon [89].
Thus, included studies should perform sufficient testing to rule out occult disease when
possible.
Each of the proposed methods for estimating the reference range allow the underlying
means of each study included in the meta-analysis to differ (this is also known as a “random
effects” assumption). In other words, variation in the observed means across studies can be
attributed to actual differences and sampling variability [67]. One can often achieve this
by carefully defining certain inclusion and exclusion criteria in the systematic review. In
particular, we assume that the studies included in the meta-analysis are a representative or
random sample from a greater “superpopulation” of potential studies and are interested in
the marginal (overall) distribution of individuals across all of these potential studies (Figure
4.1). Determining whether this sample is representative also requires investigating possible
heterogeneity sources, as described in the next section. We prefer to focus on the overall
distribution, rather than conditioning on a specific study, since it may be unclear which
theoretical study population a patient who presents to a clinic would belong to in practice.
These study-specific underlying populations would likely differ in size, though knowledge of
these true population sizes is not necessary under the random effects assumption.
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Figure 4.1: Target Population Marginal (overall) distribution and a selection of possible
transient elastography liver stiffness measurement study populations according to a random-
effects model where µ = 4, σ = 1, τ = 0.5. The distributions of study means and individuals
within each study are all normal. Each of the meta-analysis methods presented allows for
true differences between sub-populations, and the target population is the overall distribu-
tion that captures each of these.


















In the clinical scenario described previously, the overall target population consists of
healthy non-obese individuals without evidence of liver steatosis or fibrosis across all poten-
tial studies, as we aim to characterize liver stiffness measurements that would be extreme
for patients with healthy livers while incorporating the full variability found across differ-
ent populations of healthy patients. Therefore, studies of obese patients would have been
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excluded when estimating the reference range.
4.5 Investigating sources of heterogeneity
The random effects assumption described earlier to account for between-study heterogeneity
assumes that there are many possible studies and that the underlying study means follow a
distribution, typically a normal distribution. This assumption is consistent with small varia-
tions across studies such as those due to slightly different but overlapping study populations,
similar but not identical equipment, or different personnel collecting measurements. If it
is believed that the overall population can be partitioned into several distinct subpopula-
tions with different measurements, the random effects model would likely be inappropriate.
Instead, separate reference ranges corresponding to each population would be more infor-
mative. For example, if measurements are suspected to vary by subgroups, such as biologic
sex or age, separate reference ranges specific to these groups, based on stratified analysis or
meta-regression, may be more clinically meaningful. Hypothesized sources of heterogeneity
could be investigated using subgroup analyses or meta-regression methods [90], although
this often lacks power. Because the overall mean and variance across individual participants
are of equal interest when estimating the reference range, heterogeneity in the within-study
variances should also be carefully explored. For example, differences in the variances in
individual measurements within each study can be investigated visually using a forest plot
of the observed study standard deviations and their corresponding confidence intervals.
4.6 Meta-analysis methods for estimating the reference range
We previously proposed three methods for estimating the reference range using aggregate
data [88]; these methods are summarized in Table 4.1 and described in further detail in
Appendix C. The first two methods, the frequentist method, and the Bayesian posterior
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predictive interval, assume that 1) values of the variable of interest follow a normal distri-
bution for each study population; 2) the variances of individual measurements within each
study are equal across studies; 3) that the true study means are also normally distributed.
These assumptions then imply that the overall distribution across studies is also normal.
The frequentist approach involves estimating the shared within-study variance, fitting a
random-effects model on the aggregate data, and then using the estimated pooled mean and
within and between-study variances to approximate the overall distribution of individuals.
The bounds of the estimated 95% reference range are then given by finding the 2.5th and
97.5th quantiles of this overall normal distribution, assuming the estimated parameters are
fixed quantities (i.e., ignoring their uncertainty).
The Bayesian method requires fitting a random effects model on the aggregate data
where the shared within-study variance is estimated using the sampling distribution of
the sample variance. The bounds of the 95% reference range are then given by the 2.5th
and 97.5th quantiles of the posterior predictive distribution for a new individual. This
differs from the other two methods in that the reference range becomes wider with greater
uncertainty by considering the variation of parameters, consistent with the definition of the
reference range as a prediction interval. While it may be possible to introduce this behavior
with the frequentist approach using a t-distribution, the appropriate degrees of freedom are
unclear and likely require approximation. Furthermore, the degrees of freedom will depend
on both the estimated within and between-study variances and will likely be high when the
number of studies is large or when the between-study variance is small relative to the total
variance. Under those conditions, the t-distribution will strongly resemble that of a normal
distribution, meaning that incorporating estimation uncertainty will make little difference
in the width of the reference range. Additionally, depending on the application, it may
be more prudent to flag a truly healthy individual as abnormal, thus necessitating more
investigations, rather than failing to discern pathology in a sick patient. In such scenario, it
may be preferable to omit the estimation uncertainty of parameters from the width of the
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interval, because under the Bayesian approach, the estimated interval may contain greater
than 95% of measurements in the case of large estimation uncertainty (e.g., when the number
of studies is small, the between-study variance may be estimated with greater uncertainty).
Conversely, if avoiding over-diagnosis is of greater concern, the estimated interval from the
Bayesian approach may be preferred.
The frequentist and Bayesian methods also make the usual random effects assumption
that the study means (random effects) follow a normal distribution [73]. It is often incor-
rectly assumed that the central limit theorem (CLT) guarantees this [68]. The CLT only
guarantees normality of the sampling distribution of the mean from a single study, not the
overall collection of study means. Instead, this assumption should also be visually assessed.
Methods have also been developed for estimating prediction intervals for a new study effect
that do not require this normality assumption, such as those based on bootstrap sampling
methods [68, 91]. Future work could expand these methods to prediction on the individual
level.
The third aggregate data approach, the empirical approach, does not require the data
within each study to be normally distributed or equal within-study variances, only that the
overall distribution across all studies is normal. Instead, the pooled mean is estimated as a
weighted average of the study means, and the total variance is estimated as the sum of a
weighted average of the sample variances, and the sample variance of the study means. This
empirical method could also likely be used when the overall distribution is assumed to be
any other distribution that is entirely determined by its mean and variance. Furthermore,
while the methods mentioned thus far assume that the data within each study are normally
distributed, we also describe in the Appendix how to handle aggregate data that are believed
to follow a lognormal distribution.
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1A. Frequentist Approach (Aggregate Data): 
1) Estimate the pooled mean (µRE) and between-study variation (t2) using a frequentist random-effects model such 
as REML  




, where 𝑠)! is the sample variance from study 𝑖 ∈ {1,… ,𝑁} 
3) Limits of the estimated reference range: a/2 and 1 - a/2 quantiles of a 𝑁(?̂?*+ , 𝜎"! + ?̂?!)	distribution 
1B. Frequentist Approach (Individual Participant Data): 
1) Fit a frequentist random-effects model (linear mixed model) directly using the individual participant data 
2) ?̂?! = Estimated variance of the random effects 
3) 𝜎"!	= Estimated residual variance  
4) ?̂?*+ = Estimated pooled mean (fixed effect) 
5) Limits of the estimated reference range: a/2 and 1 - a/2 quantiles of a 𝑁(?̂?*+ , 𝜎"! + ?̂?!)	distribution 
1C. Bayesian Approach (Aggregate Data): 
1) 𝑦5) 	~	𝑁 7𝜃) ,
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2) Place N(0, 1000) prior on µRE and Uniform(0, 100) priors on s and t 
3) Use MCMC sampler (such as JAGS, Stan, or WinBugs) to sample from posterior predictive distribution for a 
new individual: 𝑦$-.	~	𝑁(?̂?*+ , 𝜎"! +	 ?̂?!) 
4) Limits of the estimated reference range: a/2 and 1 - a/2 quantiles of ynew samples 
1D. Bayesian Approach (Individual Participant Data): 
1) 𝑦)/ 	~	𝑁(𝜃) , 𝜎!), 𝜃) 	~	𝑁(𝜇*+ , 𝜏!) 
2) Place N(0, 1000) prior on µRE and Uniform(0, 100) priors on s and t 
3) Use MCMC sampler (such as JAGS, Stan, or WinBugs) to sample from posterior predictive distribution for a 
new individual: 𝑦$-.	~	𝑁(?̂?*+ , 𝜎"! +	 ?̂?!) 
4) Limits of the estimated reference range: a/2 and 1 - a/2 quantiles of ynew samples 
1E. Empirical Approach (Aggregate Data):  

















   
2) Limits of the estimated reference range: a/2 and 1 - a/2 quantiles of a 𝑁??̂?-01, 𝜎"4,-01! @	distribution 
1F. Empirical Approach (Individual Participant Data):  
1) Empirically estimate the pooled mean and total variance as the observed mean and variance of the pooled 















	   
2) Limits of the estimated reference range: a/2 and 1 - a/2 quantiles of a 𝑁??̂?-01, 𝜎"4,-01! @	distribution 
Simulation results suggest that each of the proposed aggregate data approaches perform
similarly when the between-study heterogeneity is relatively small, and the number of stud-
ies in the meta-analysis is large (at least 20) [88]. However, some caution should be used in
cases of large between-study heterogeneity or very few studies. It may be more appropriate
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to construct reference ranges separately for subgroups or studies of different populations
in these situations. In particular, if there is unexplained between-study heterogeneity that
comprises approximately 30-50% or more of the total estimated variance, it is important
to consider the interpretability of the estimated reference range carefully. While the equal
within-study variation assumption made by the frequentist and Bayesian methods is ar-
guably quite strong, Siegel et al. demonstrated through simulations that these methods
might be robust to small differences in the true variances across studies [88]. However, if
the within-study variances plausibly differ according to some characteristic of the studies,
such as the proportion of males vs. females, separate reference ranges for these groups may
be more clinically meaningful regardless of the distributional assumptions of the method
used.
4.7 Applied example
We now re-analyze the data used in the clinical scenario [7] in order to construct a reference
range that reflects natural variability across healthy individuals rather than the uncertainty
in the estimated pooled mean.
4.7.1 Defining the population of interest
Individuals were included in the original analysis if they had a BMI less than 30, and did not
have hypertension, dyslipidemia, hepatic steatosis on ultrasound, or diabetes mellitus. This
resulted in 3652 individuals across 20 studies. Because one of these studies only contained
four individuals meeting the inclusion criteria, we further excluded these four patients from
the analysis. This resulted in a final dataset containing 3648 individuals across 19 studies.
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4.7.2 Derivation of aggregate data
In order to replicate the scenario where only aggregate data were available, rather than IPD,
we summarized the data within each study by the mean, standard deviation, and sample
size (Table C.2).
4.7.3 Application of methods
We present a typical forest plot for the study-specific means and pooled mean, with their
corresponding confidence intervals in Figure 4.2. The pooled mean was estimated using
the aggregate data and a frequentist random effects model (using REML estimation) im-
plemented in the R package “meta” [75]. Because liver stiffness measurements cannot be
negative and the observed distribution of measurements was slightly right-skewed, we first
log-transformed the liver stiffness measurements and then exponentiated the results for
the means and 95% confidence intervals. Because we were using aggregate data, this log-
transformation required using the approximation described in the Appendix and Table C.1.
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Figure 4.2: Forest Plot of Study Means for Clinical Scenario Estimated mean (95% con-
fidence interval) for each transient elastography liver stiffness measurement study and es-
timated pooled mean (95% confidence interval) based on aggregate data. All calculations














































We next applied each of the proposed methods for estimating the 95% reference range
(Table 4.2) using the aggregate data. As previously mentioned, we used the R package
“meta”[75] to fit the frequentist random-effects model with aggregate data. We implemented
the Bayesian models in JAGS using the R packages “rjags” and “coda” [51, 52]. For the
Bayesian models, we ran two chains with 100,000 iterations each and a burn-in period of
5,000 iterations and assessed convergence based on trace plots, the MCMC error, and the
potential scale reduction factor. All analyses were conducted using R version 3.6.3 [50].
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Table 4.2: Reference Range Results for Clinical Scenario with Aggregate Data Estimated
95% reference ranges for liver stiffness measurement using each of the methods presented
with aggregate data. The reference ranges were estimated on the log-scale, and the resulting
intervals were exponentiated.
Method Estimated 95% Reference Range
Frequentist (2.55 kPa, 7.90 kPa)
Bayesian (2.52 kPa, 7.94 kPa)
Empirical (2.57 kPa, 7.86 kPa)
The estimated reference ranges were similar across each of the methods used (Table 4.2,
Figure 4.3). The Bayesian posterior predictive interval was slightly wider, followed by the
frequentist method, then the empirical approach. We would expect the Bayesian method
to give a wider reference range as it incorporates uncertainty in the parameter estimates.
Figure C.1, included in the Appendix, displays the observed standard deviations of the
log of liver stiffness within each study and their respective 95% confidence intervals. This
allows us to assess the equal within-study variance assumption imposed by the frequentist
and Bayesian methods for estimating the reference range. In general, this figure shows
that most of the observed study standard deviations are very similar and that there is a
high degree of overlap in their respective confidence intervals. However, studies 9 and 16
look to have a slightly different standard deviations from the other studies. We therefore
performed a sensitivity analysis where we removed studies 9 and 16 and compared the
estimated reference ranges with and without them. The results of this sensitivity analysis
are given in Table C.3 in the Appendix; the results with and without these two studies are
similar.
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Figure 4.3: Forest Plot of Results for Clinical Scenario 95% confidence interval for each
study mean, 95% frequentist prediction interval for a new individual’s transient elastography
liver stiffness measurement by study, 95% confidence interval for the pooled mean, 95%
prediction interval for a new study mean, and estimated 95% reference ranges using the




























95% CI for Study Mean
95% Prediction Interval
95% CI for Pooled Mean
95% Prediction Interval for New Study Mean
Frequentist AD Reference Range
Bayesian AD Reference Range
Empirical AD Reference Range
Each of the estimated reference ranges can be interpreted as the predicted interval in
which we would expect 95% of liver stiffness measurements of healthy individuals to fall.
For example, based on the Bayesian individual participant data reference range, we would
expect 95% of healthy patients to have liver stiffness measurements between 2.52 kPa and
7.94 kPa. Therefore, if our hypothetical patient who is concerned about his family history
of liver fibrosis, had a liver stiffness measurement of 9.00 kPa, this may necessitate further
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investigations, as this degree of liver stiffness is atypical of a healthy individual.
The 95% confidence interval for the pooled mean ([4.29 kPa, 4.69 kPa]), is much narrower
than any of the estimated reference ranges. This demonstrates the difference that incorpo-
rating natural within-person variability makes when constructing the reference range. This
is also true when comparing the estimated reference ranges to the frequentist 95% prediction
interval for the mean of a new study: (3.67 kPa, 5.49 kPa) instead of the measurement of
an individual [67,68]. This interval is wider than the 95% confidence interval for the pooled
mean, as it reflects between-study variance and its corresponding estimation uncertainty.
However, unlike the reference ranges, it still does not reflect within-study variation across
healthy individuals. We can also compare the results to the 2.5th and 97.5th quantiles of the
individual measurements, ignoring study assignment: (2.70 kPa, 7.49 kPa). The estimated
reference ranges that incorporate study assignment are slightly wider than this because they
allow for between-study variation and the possibility of more extreme measurements in a
future study. The confidence interval for the pooled mean and the prediction interval for
a new study mean are far narrower and do not capture healthy individuals’ full variation.
The different interpretations of the reference ranges, the confidence interval for the pooled
mean, and the prediction interval for a new study are summarized in Table 4.3.
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Interval Pooled Mean  95% Prediction Interval for a New 
Study   
 
95% Reference Range (proposed) 
Interpretation Frequentist 95% Confidence 
Interval (a, b):  
“We are 95% confident that the mean 
across all studies is between a and b.”  
 
Prediction interval (c,d): 
“The mean of a new study (from the same 
overall target population) is expected to fall 
between c and d with 95% probability.”  
 
Reference range (e,f): 
“The measurement of a new individual is expected to 
fall between e and f with 95% probability.”  
Bayesian 95% Credible Interval 
(a,b):  
“The true mean across all studies lies 
between a and b with 95% 
probability.”  
 
Assumptions Under a random-effects model:  
• Study means follow a normal 
distribution1 
• The means are exchangeable 
across studies  
• The studies included are 
representative of some 
superpopulation of interest 
 
Under a random-effects model:  
• Study means follow a normal distribution 
• The means are exchangeable across 
studies 
• The studies included are representative of 
some superpopulation of interest 
 
Frequentist:  
• Measurements within each study follow a normal 
distribution 
• Study means follow a normal distribution and 
are exchangeable 
• Constant within-study variance 
Bayesian: 
• Same as frequentist  
Empirical:  
• Measurements across all studies follow a normal 
distribution 
Estimation Frequentist:  
?̂?!" ± 𝑡#$%;%$'.')/+	𝑆𝐸(	?̂?!") 
(where N = # of studies) 
Frequentist: 
?̂?!" ± 𝑡#$+;%$'.')/+*𝑉𝑎𝑟. (?̂?!") + ?̂?+  [67] 
See Box 1 
Bayesian:  
2.5th and 97.5th quantiles of the 
posterior distribution of the pooled 
mean (𝜇!") 
Bayesian:  
2.5th and 97.5th quantiles of the posterior 
predictive distribution of a new study: 
𝑁(𝜇!" , 𝜏#), where 𝜇!" and 𝜏# refer to their 
posterior distributions 
 
1 * The method proposed by DerSimonian and Laird [74] does not require the study means to be normally distributed but can underestimate the between-study variance, particularly when the number of 
studies is small [76] 
4.8 Estimating the reference range using individual participant data
(IPD)
All three approaches are designed for the meta-analysis of aggregate data, where only the
study means, standard deviations, and sample sizes are known. Because of this, we also
include how the reference range could be calculated using IPD without first aggregating
the data (i.e., a one-step approach) (Table 4.1). These approaches are one-step analogs of
each of the three approaches described previously, though the two versions of the empirical
approach are in theory equivalent. The estimated reference ranges based on individual
participant data ultimately serve as a “gold-standard”.
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Furthermore, individual participant data allows for a more detailed exploration of the
modeling assumptions. Each of the methods previously discussed assumes that the in-
dividuals across all studies follow an overall normal distribution. Both the Bayesian and
frequentist approaches also assume that the data within each study are normally distributed
and that the within-study variances are equal across studies. Unlike with aggregate data,
if IPD are available, these normality assumptions can be visually assessed using methods
such as histograms and normal Q-Q plots. Because of this, access to IPD even for 1 or
2 studies could be valuable in investigating these distributional assumptions before using
an aggregate data method to estimate the reference range. Similarly, with aggregate data,
we cannot directly log-transform the individual measurements. Instead, the approximation
given in the Appendix Table C.1 must be used.
4.8.1 Applied example with individual participant data
Here, we present the results for the clinical scenario using both the aggregate (two-step)
approaches as well as the one-step frequentist and Bayesian approaches based on the IPD.
In all cases, the data are first log-transformed (before aggregating) and the resulting ranges
are exponentiated. While the aggregate data approaches are still valid even when individual
participant data are available, the one-step (IPD) approaches are the gold standard.
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Table 4.4: Reference Range Results for Clinical Scenario with IPD Estimated 95% reference
ranges for liver stiffness measurement using IPD. The reference ranges were estimated on
the log-scale and the resulting intervals were exponentiated
Method Estimated 95% Reference Range
Frequentist AD (2.62 kPa, 7.74 kPa)
Bayesian AD (2.61 kPa, 7.79 kPa)
Empirical AD (2.64 kPa, 7.69 kPa)
Frequentist IPD (2.63 kPa, 7.72 kPa)
Bayesian IPD (2.52 kPa, 7.94 kPa)
Empirical IPD (2.64 kPa, 7.69 kPa)
A histogram of the pooled log liver stiffness measurements (Figure C.3) as well as his-
tograms by study (Figure C.4) are included in the Appendix and demonstrate no clear
violations to the overall and within-study normality assumptions described previously. We
were able to assess these normality assumptions using IPD, whereas this would not be possi-
ble with only aggregate data. As expected, the frequentist method using IPD gave a slightly
narrower estimated reference range than the Bayesian method with IPD. With IPD avail-
able, we directly obtained the mean and standard deviation on the log scale for each study.
This is different from computing the mean and standard deviation in the log scale using
the methods presented in Appendix Table C.1 with only the reported mean and standard
deviation in the original scale. Because the log-transformation differed between this analy-
sis and the aggregate data analysis presented previously in Table 4.2, we would expect the
results to be slightly different from the previous analysis even amongst the aggregate data
approaches. Notably, the results using the aggregate data are comparable to those based
on the IPD (Table 4.4). This supports the validity of the aggregate data approaches in this
case, an important point given that IPD are rarely available for all studies included in a
meta-analysis. We also repeated the sensitivity analysis described in the previous section
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with the IPD, and again observed similar results with and without studies 9 and 16, as
shown in the Appendix (Table C.4).
4.9 Interpretation of results
Because there has been little guidance in the literature on estimating reference ranges from a
meta-analysis, many meta-analytical studies have reported the pooled mean as a “reference
value” [8, 12, 53]. While the pooled mean can establish a point of reference, it does not
capture natural variation across healthy individuals. As a result, some studies have also
reported the 95% confidence interval for the pooled mean as a “reference range” [7, 61, 62],
although this better reflects the uncertainty in the estimated pooled mean, not the range
of predicted values for a new individual. For example, as the number of studies included in
the meta-analysis increases, we would expect the confidence interval for the pooled mean
to narrow, reflecting increased precision in the estimate. However, we would not expect the
width of the estimated reference range to approach zero as the total sample size increases.
Similarly, some have recently advocated for the reporting of a prediction interval for the
mean or effect size of a new study when conducting meta-analyses in order to better describe
between-study heterogeneity [65–68]. Riley et al. [67] describe a random effects meta-
analysis example where there is a statistically significant pooled treatment effect, but the
prediction interval for the treatment effect in a new study is [-0.79, 0.09]. They explain that
the majority of the interval being below zero suggests that the treatment in question works
in most settings, but that the small amount of the interval falling above zero indicates that
the treatment may not be effective in some situations [67]. This example clearly illustrates
how the confidence interval for the pooled mean does not necessarily represent the variation
across study populations. However, the prediction interval for the mean of a new study still
does not reflect the full variation on the individual participant level and would therefore
not be suitable as a reference range either.
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Figure 4.4: Comparison of Intervals Estimated in Meta-Analysis 95% Confidence interval
for the pooled mean, 95% prediction interval for the mean of a new study, and estimated
95% reference range for µ̂ = 4, σ̂ = 1, and τ̂ = 0.5 and different within study sample size











































N = 10, n = 30
N = 10, n = 500
N = 50, n = 500
The differences in these intervals are illustrated in Figure 4.4, which shows the 95%
confidence interval for the pooled mean, 95% prediction interval for a new study, and the
estimated 95% reference range based on the same estimates of the pooled mean and within
and between-study variances, but varying the numbers of studies included in the meta-
analysis (N) and the number of individuals within each study (n). We can see that as the
number of studies or number of participants within each study increases, the confidence
interval for the pooled mean narrows. The prediction interval for a new study mean also
narrows slightly, but this is due to greater perceived precision in the estimated parameters.
Figure 4.4 also shows the estimated 95% reference ranges for each of these meta-analyses
when using the frequentist method proposed by Siegel et al. [88]. This method does not
incorporate uncertainty in the estimated parameters, so the width of the reference range
does not change for different sample sizes. However, the Bayesian posterior predictive
reference range interval, also proposed by Siegel et al. [88], can naturally incorporate the
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uncertainty in the estimated parameters. Despite this difference, the estimated reference
ranges in Figure 4.4 are still wider than other intervals. This is because they reflect both the
estimated within-study and between-study variances, rather than only the between-study
variance as does the prediction interval for the mean of a new study, or neither as does the
confidence interval for the pooled mean.
4.10 Certainty about the estimated reference range
To be able to apply research evidence to patient care properly, evidence users (clinicians,
patients, and guideline developers) need to know how certain or trustworthy is the evidence.
Therefore, when a reference range is estimated, we need to consider applicability, risk of
bias, heterogeneity and precision [92]. If possible, studies at high risk of bias (e.g., due
to poor ascertainment of the measured laboratory test or because of a large proportion
of patients lost to follow up) [93] could be excluded from the reference range estimation.
If biased studies are included, the estimated between-study heterogeneity will reflect both
true clinical differences in the study populations and heterogeneity caused by this bias [67].
If excluding these studies is not feasible, and we are left with a reference range estimated
from studies at high risk of bias, certainty in this range will be low. If heterogeneity
between the studies used to estimate the range was high and not explained by subgroup
analyses, certainty will also be low. If the total sample size of included studies was small,
the estimation of this range will also be imprecise and warrants lower certainty.
Furthermore, the Bayesian posterior predictive interval method for estimating the ref-
erence range incorporates the estimation uncertainty of parameters into the width of the
interval, while the other methods do not. However, as previously mentioned, investigators
primarily concerned about failing to diagnose a non-healthy patient may prefer not to use
this method as the estimated reference range can contain greater than 95% of individual
measurements. In this case, one could estimate the reference range using the frequen-
tist or empirical method and then investigate uncertainty by comparing the results to the
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Bayesian posterior predictive interval. If the Bayesian posterior predictive interval is con-
siderably wider than the interval estimated using one of the other two methods, this would
suggest a high degree of estimation uncertainty. However, there is still a need for further
work to develop methods for quantifying the degree of uncertainty in the reference range
limits estimated from a meta-analysis.
4.11 Discussion
This empirical application introduces the aggregate data approaches to estimating reference
ranges proposed by Siegel et al. [88] and two one-step approaches using individual partici-
pant data. Overall, the results across all methods are similar in the clinical scenario, demon-
strating that the aggregate data approaches with the corresponding log-transformation pro-
vide an adequate approximation to the results using the individual participant data. Each
of the proposed methods is relatively easy to use. The Bayesian methods (both one and
two-step) differ from the other methods in that the width of the estimated ranges increases
with greater uncertainty. The frequentist and empirical approaches also do not require
setting prior distributions for the model parameters and may be easier to implement in
practice than the Bayesian methods. The frequentist methods can be implemented using
existing software packages, while the empirical approach only uses simple formulas based
on the aggregate data.
The assumptions used by each of the proposed methods should be considered when
estimating the reference range, preferably by investigating distributional assumptions using
IPD from at least 1-2 data sets, and further work is still needed to address situations
where these assumptions are not met. However, each of the methods provides information
about the variability of a measurement across healthy individuals beyond that provided by
the pooled mean. The applied example using liver stiffness measurements also illustrates
how these methods more accurately describe variation across healthy individuals than the
confidence interval for the pooled mean or the prediction interval for the mean of a new
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5.1 Summary of major findings
This thesis proposed several methods for the meta-analysis of prevalence and normative
data, two areas that have previously gained less attention in meta-analysis than the meta-
analysis of randomized controlled trials or diagnostic test studies. Chapter 2 proposed a
novel parameterization of a multivariate meta-analysis model for the joint meta-analysis of
the prevalence of an overall outcome as well as several subtype outcomes. This parameter-
ization accounted for the natural constraint that neither the underlying prevalence nor the
observed counts of the subtypes can exceed those of the overall outcome. Simulation stud-
ies demonstrated that accounting for these natural constraints as well as the correlations
between outcomes can reduce bias and increase precision, compared to both analyzing the
outcomes univariately. This was also true when comparing this new parameterization to
a multivariate model that does not account for these natural constraints. The simulations
demonstrated these gains were largest in the presence of missing data, particularly when
these data were missing at random. We hypothesize the reduced bias and increased preci-
sion are likely driven by the truncation of density in regions where the subtype outcomes
would have higher prevalences than the overall outcome. These methods were demonstrated
75
using data from Markland et al. [19] on the prevalence of stress, urgency, or any type of
urinary incontinence.
Chapter 3 proposed methods for estimating a reference range from a meta-analysis.
No methodological guidance previously existed in the literature for estimation reference
ranges using the results from multiple studies, particularly when only aggregate data are
available. Siegel et al. [88] proposed three main approaches for estimating the meta-analysis
that only require information on the sample size, observed mean, and standard deviation
from each study included in the meta-analysis: a frequentist, a Bayesian, and an empirical
approach. Simulation studies demonstrated that all three methods perform well in capturing
the middle 95% of values when the true overall distribution was normal, the number of
studies was relatively large (e.g. at least 20), and the between-study variance was relatively
low compared to the overall variance (less than 30-50%). This was the case for both equal
and unequal within-study variances. These methods were illustrated using two applied
examples: pediatric waking time after sleep onset (WASO) and frontal subjective postural
vertical measurements.
Finally, because Chapter 3 is written primarily for a statistical audience, Chapter 4
provides a guide aimed at a clinical and epidemiological audience describing how the three
methods proposed in Chapter 3 can be used. Chapter 4 also extends these methods to the
case where individual participant data are available. These methods are presented in the
context of a clinical scenario about a patient at risk for liver fibrosis and who may undergo
a non-invasive measure of liver stiffness for which there has previously been no established
reference range. In this chapter, the concepts of heterogeneity, applicability, the target
population, and the reference range’s interpretation are explored more deeply. Finally, in
the results for the clinical scenario, the estimated reference ranges using aggregate data are
very similar to those using individual participant data, suggesting that the aggregate data
approaches provide a valid alternative when individual participant data are not available.
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5.2 Future research
The findings described in the previous section lead to many opportunities for future work.
The first area stems from the work presented in Chapter 2 on reparameterizing multivariate
meta-analysis models for binary outcomes to account for natural constraints in the data:
5.2.1 Bayesian Multivariate Meta-analysis of Serologic Test Accuracy: With Ap-
plication to COVID-19
Serologic tests may measure the presence of multiple types of antibodies to determine
whether a patient has a disease. For example, a recent systematic review and meta-analysis
of COVID-19 antibody tests [94] assessed the sensitivity and specificity of different COVID-
19 serologic tests when detecting IgG, IgM, or either type of antibody. In this case, the
sensitivity when detecting either type of antibody cannot exceed the sensitivity when detect-
ing either antibody individually, with the converse true for the specificities. Methods have
previously been developed for the multivariate meta-analysis of diagnostic tests that jointly
model sensitivity and specificity in order to account for the correlation between these two
measures [4,5]. Hong et al. [42] also developed methods for meta-analysis in the case of both
multiple treatments and multiple outcomes that could be easily applied to the diagnostic
test setting. However, none of these methods account for the natural constraints described
previously. We will extend the model proposed in Chapter 2 for multivariate meta-analysis
of prevalences to the diagnostic test setting by also allowing for sensitivity and specificity
to be jointly modeled in addition to the multiple antibody types.
5.2.2 Estimating the Reference Range from a Fixed Effects Meta-Analysis
The frequentist and Bayesian methods proposed in Chapter 3 for estimating the reference
range from a meta-analysis are based on a random effects model. However, if only a small
number of studies are included in the meta-analysis, it may be impossible to reliably estimate
the between-study variance. Alternatively, the random effects normality assumption for the
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study means may not appear reasonable in some cases. In these settings, one may prefer
to estimate the reference range using a fixed effects model [64], which does not assume
any particular relationship between study means. Cao et al. [95] recently proposed a novel
method in addition to highlighting the empirical method proposed by Siegel et al. [88] for
estimating the reference range from a meta-analysis using a fixed effects model. Further
work is needed to establish when avoiding the assumptions made by the random effects
model may be beneficial, as well as in which cases one of the two fixed effects methods
proposed may be preferred over the other.
5.2.3 Incorporating Covariates when Estimating the Reference Range from a
Meta-Analysis
When estimating the reference range, it is important to assess heterogeneity to establish
whether it may be preferable to estimate separate reference ranges for subgroups, such as
males and females. However, how these separate reference ranges are estimated requires
further exploration. If only aggregate data are available and covariates are on the study
level (e.g. study country, age groups), reference ranges can be estimated individually using
separate models. However, if either the within or between-study variances can be assumed
to be the same across subgroups, it may be more efficient to borrow information across
groups by fitting a single meta-regression model. We will explore the relative benefits of
different meta-regression models under a variety of settings as well as whether using model
selection criteria (e.g. DIC in Bayesian settings) results in an appropriate choice of reference
range model.
5.2.4 Estimating the Reference Range when Both Aggregate Data and IPD are
Available
Chapter 3 proposes methods for estimating the reference range from a meta-analysis when
only aggregate data are available and Chapter 4 extends these methods to cases where
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IPD are available. However, if a meta-analysis contained some studies with IPD and some
with only aggregate data, using the currently proposed methods, the studies with IPD
would first need to be aggregated, then the three methods proposed in Chapter 3 could be
applied. Future work is needed to develop methods for estimating the reference range that
could be fit directly on both the aggregate data and IPD. This could potentially lead to
greater efficiency and may allow for the use of individual patient level covariates while still
incorporating information from the aggregated studies.
5.2.5 Nonparametric Estimation of the Reference Range from a Meta-Analysis
All of the proposed methods for estimating reference ranges [88,95] make some parametric
assumptions, either regarding the distributions of individuals’ measurements within studies,
the overall distribution across studies, or the distribution of the means of measurements
across studies. The frequentist and Bayesian methods described in Chapters 3 and 4 make
assumptions about all three. In some cases, these parametric assumptions may be deemed
inappropriate, leading to the need to develop non-parametric methods for estimating the
reference range.
5.2.6 Software
Finally, while the Web Supplement for the paper by Siegel et al. [88] presented in Chapter
3 provides code for implementing each of the proposed methods, developing software such
as an R package or SAS macro will be important for increasing their use. The intended
audience of Chapter 4 is comprised of clinicians and epidemiologists who may feel more
comfortable implementing the proposed methods if they have access to user-friendly soft-
ware. Eventually, this software will provide options for estimating the reference range from
a meta-analysis using a variety of different methods depending on the modeling assumptions
desired and availability of IPD.
79
References
[1] AB Haidich. Meta-analysis in medical research. Hippokratia, page 9, 2010.
[2] Irbaz Bin Riaz, Muhammad Shahzeb Khan, Haris Riaz, and Robert J. Goldberg. Dis-
organized Systematic Reviews and Meta-analyses: Time to Systematize the Conduct
and Publication of These Study Overviews? The American Journal of Medicine,
129(3):339.e11–339.e18, March 2016.
[3] D Jackson, R Riley, and I R White. Multivariate meta-analysis: Potential and promise.
Statistics in Medicine, 30(20):2481–2498, 2011.
[4] Haitao Chu, Lei Nie, Stephen R. Cole, and Charles Poole. Meta-analysis of diagnostic
accuracy studies accounting for disease prevalence: Alternative parameterizations and
model selection. Statistics in Medicine, 28(18):2384–2399, 2009.
[5] H Chu, H Guo, and Y Zhou. Bivariate random effects meta-analysis of diagnostic
studies using generalized linear mixed models. Med Decis Making, 30(4):499–508, 2010.
[6] Q Lian, J S Hodges, and H Chu. A bayesian hierarchical summary receiver operat-
ing characteristic model for network meta-analysis of diagnostic tests. Journal of the
American Statistical Association, page in press, 2019.
[7] Fateh Bazerbachi, Samir Haffar, Zhen Wang, Joaqúın Cabezas, Maria Teresa Arias-
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Appendix A
Supplementary Materials for “A
Bayesian Multivariate Meta-Analysis of
Prevalence Data”
A.1 Marginal Event Rate for Subtypes
In this section we derive Equation (2.11), which describes how to find the population aver-
aged prevalence (πj) for each subtype j.
This is given by:





Φ(µ0 + σ0z0)Φ(µj + σ
∗
j zj)φ(z0, zj)dz0dzj , (A.1)
where φ(z0, zj) denotes the probability density function of a bivariate standard normal
distribution.
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This is equivalent to:
E[P (Y1 ≤ µ0 + σ0Z0)P (Y2 ≤ µj + σ∗jZj)]
=E[P (Y1 − σ0Z0 ≤ µ0)P (Y2 − σ∗jZj) ≤ µ∗j ],
(A.2)
where Y1 and Y2 are two independent standard normal random variables. Because






, where T1 and T2 are both distributed N(0, 1) with correlation
ρ. Therefore, this is equal to:
E







Since Z0 and Zj are distributed bivariate standard normal, we can see that (T1, T2) are
distributed bivariate normal with means (0,0), variances (1,1) and some Cov[T1, T2].
We can then solve for this covariance:


































is equal to Σ∗1,j+1, which we are already estimating. Therefore, we









where X and Y are distributed bivariate normal with means = (0, 0), variances = (1, 1),






A.2 Tables and Figures
Figure A.1: Posterior Density Plot Posterior prevalence density plots for overall UI and







































Table A.1: Case Study Data Author, publication year, sample size (N), and counts for
any urinary incontinence (UIPrev), stress incontience (SUIPrev), or urgency incontinence
(UUIPrev)
Author PubYear N UIPrev SUIPrev UUIPrev
1 Araki 2005 3734 624 456 76
2 Azuma 2008 975 220 42 9
3 Bailey 2010 200 55 28 28
4 Bo 2011 685 181 47 10
5 Buschbaum 2002 149 75 23 18
6 Davis 1999 563 175
7 Fischer 1999 274 72 51 7
8 Fitzgerald 2000 1113 234 197
9 Fitzgerald 2002 269 78 20 1
10 Fultz 2005 3364 1480 148 548
11 Liao 2007 445 120 62 8
12 Liao 2009 907 82 25 14
13 Nygaard 1997 791 127 23 17
14 Liu 2014 5433 1684
15 Kaya 2016 281 51 25 14
16 Kim 2016 5928 445
17 Hart 1999 1113 234
18 Lam 1992 2631 510
19 Palmer 2015 113 60
20 Pierce 2017 2907 930
21 Peyrat 2002 1700 357 161 21
22 Saadoun 2006 2640 554
23 Sexton 2009 2820 722
24 Singh 2013 3000 657 484 62
25 Wan 2016 636 297 122 73
26 Zhang 2013 1070 482 349 225
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Table A.2: (N = 30, ni = 500, MCAR) Bias, 95% credible interval width (CIW) and
coverage probability (Cov.) for univariate model, original multivariate model, and new
parameterization across 2000 simulations containing 30 studies, where ni = 500, the true
prevalences are (0.3, 0.15, 0.05), and data are missing completely at random (MCAR).
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5),ρ = 0
Univariate 0.003 0.118 0.95 0.009 0.121 0.96 0.007 0.070 0.95
Original 0.004 0.120 0.96 0.007 0.098 0.96 0.008 0.064 0.95
New Param. 0.004 0.121 0.96 0.002 0.093 0.96 0.005 0.057 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.4
Univariate 0.003 0.118 0.96 0.010 0.138 0.96 0.009 0.083 0.97
Original 0.003 0.119 0.96 0.007 0.104 0.96 0.007 0.067 0.96
New Param. 0.004 0.121 0.96 0.003 0.100 0.96 0.005 0.061 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.8
Univariate 0.003 0.118 0.96 0.011 0.153 0.96 0.011 0.094 0.96
Original 0.003 0.118 0.96 0.006 0.106 0.95 0.006 0.063 0.95
New Param. 0.003 0.119 0.96 0.004 0.103 0.95 0.005 0.059 0.95
σ = (0.5, 1, 1),ρ = 0
Univariate 0.003 0.118 0.95 0.013 0.159 0.97 0.017 0.122 0.97
Original 0.004 0.121 0.96 0.015 0.147 0.95 0.020 0.126 0.96
New Param. 0.005 0.121 0.96 0.003 0.119 0.96 0.009 0.085 0.96
σ = (0.5, 1, 1),ρ = 0.4
Univariate 0.003 0.118 0.96 0.016 0.181 0.97 0.020 0.139 0.96
Original 0.004 0.120 0.96 0.014 0.153 0.97 0.020 0.127 0.95
New Param. 0.004 0.121 0.96 0.004 0.126 0.96 0.011 0.093 0.95
σ = (0.5, 1, 1),ρ = 0.8
Univariate 0.003 0.118 0.96 0.017 0.198 0.97 0.023 0.155 0.96
Original 0.003 0.119 0.96 0.010 0.146 0.97 0.015 0.111 0.96
New Param. 0.003 0.120 0.96 0.005 0.129 0.95 0.010 0.092 0.97
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Table A.3: (N = 30, ni = 500, MAR) Bias, 95% credible interval width (CIW) and coverage
probability (Cov.) for univariate model, original multivariate model, and new parameteri-
zation, across 2000 simulations containing 30 studies, where ni = 500, the true prevalences
are (0.3, 0.15, 0.05), and data are missing at random (MAR).
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5),ρ = 0
Univariate 0.003 0.118 0.954 0.009 0.121 0.963 0.007 0.070 0.953
Original 0.004 0.120 0.959 0.007 0.098 0.958 0.008 0.064 0.949
New Param. 0.004 0.121 0.963 0.002 0.093 0.962 0.005 0.057 0.960
σ = (0.5, 0.5, 0.5),ρ = 0.4
Univariate 0.004 0.118 0.960 0.078 0.143 0.309 0.036 0.092 0.503
Original 0.004 0.119 0.964 0.014 0.114 0.946 0.012 0.074 0.942
New Param. 0.005 0.121 0.967 0.005 0.096 0.956 0.006 0.056 0.959
σ = (0.5, 0.5, 0.5),ρ = 0.8
Univariate 0.003 0.118 0.960 0.092 0.154 0.234 0.044 0.098 0.381
Original 0.004 0.118 0.961 0.009 0.106 0.953 0.008 0.061 0.945
New Param. 0.004 0.119 0.963 0.007 0.101 0.953 0.006 0.055 0.948
σ = (0.5, 1, 1),ρ = 0
Univariate 0.004 0.118 0.954 0.069 0.187 0.630 0.039 0.150 0.804
Original 0.005 0.121 0.962 0.036 0.201 0.951 0.038 0.180 0.923
New Param. 0.005 0.121 0.961 0.003 0.111 0.965 0.011 0.081 0.954
σ = (0.5, 1, 1),ρ = 0.4
Univariate 0.004 0.118 0.963 0.088 0.199 0.487 0.051 0.161 0.661
Original 0.005 0.120 0.966 0.024 0.173 0.959 0.028 0.147 0.934
New Param. 0.005 0.121 0.965 0.006 0.120 0.961 0.012 0.084 0.948
σ = (0.5, 1, 1),ρ = 0.8
Univariate 0.003 0.118 0.957 0.111 0.205 0.322 0.062 0.164 0.510
Original 0.004 0.119 0.959 0.014 0.139 0.945 0.014 0.098 0.947
New Param. 0.004 0.120 0.962 0.009 0.126 0.947 0.010 0.081 0.945
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Table A.4: (N = 10, ni = 100, MCAR) Bias, 95% credible interval width (CIW) and
coverage probability (Cov.) for univariate model, original multivariate model, and new
parameterization across 2000 simulations containing 10 studies, where ni = 100, the true
prevalences are (0.3, 0.15, 0.05), and data are missing completely at random (MCAR).
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5),ρ = 0
Univariate 0.009 0.226 0.96 0.040 0.332 0.97 0.052 0.314 0.96
Original 0.012 0.237 0.97 0.033 0.278 0.97 0.053 0.289 0.96
New Param. 0.013 0.241 0.97 0.007 0.198 0.98 0.022 0.162 0.98
σ = (0.5, 0.5, 0.5),ρ = 0.4
Univariate 0.008 0.225 0.96 0.046 0.363 0.98 0.059 0.340 0.97
Original 0.011 0.235 0.97 0.036 0.299 0.97 0.054 0.297 0.96
New Param. 0.012 0.240 0.97 0.008 0.210 0.97 0.023 0.170 0.97
σ = (0.5, 0.5, 0.5),ρ = 0.8
Univariate 0.008 0.225 0.96 0.048 0.378 0.97 0.067 0.364 0.96
Original 0.009 0.232 0.97 0.034 0.298 0.97 0.055 0.297 0.97
New Param. 0.011 0.235 0.97 0.010 0.214 0.97 0.025 0.176 0.97
σ = (0.5, 1, 1),ρ = 0
Univariate 0.007 0.225 0.95 0.051 0.389 0.97 0.077 0.397 0.96
Original 0.011 0.238 0.97 0.052 0.358 0.96 0.086 0.384 0.94
New Param. 0.011 0.240 0.97 0.004 0.226 0.97 0.028 0.192 0.96
σ = (0.5, 1, 1),ρ = 0.4
Univariate 0.006 0.224 0.96 0.058 0.421 0.98 0.081 0.408 0.96
Original 0.009 0.234 0.97 0.054 0.374 0.97 0.083 0.382 0.95
New Param. 0.010 0.237 0.97 0.006 0.238 0.97 0.029 0.200 0.96
σ = (0.5, 1, 1),ρ = 0.8
Univariate 0.006 0.223 0.96 0.060 0.436 0.97 0.082 0.413 0.97
Original 0.008 0.229 0.96 0.047 0.364 0.97 0.073 0.360 0.96
New Param. 0.008 0.231 0.96 0.007 0.244 0.96 0.030 0.207 0.96
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Table A.5: (N = 10, ni = 100, MAR) Bias, 95% credible interval width (CIW) and coverage
probability (Cov.) for univariate model, original multivariate model, and new parameteri-
zation across 2000 simulations containing 10 studies, where ni = 100, the true prevalences
are (0.3, 0.15, 0.05), and data are missing at random (MAR).
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5),ρ = 0
Univariate 0.009 0.226 0.96 0.089 0.342 0.83 0.070 0.332 0.86
Original 0.012 0.238 0.97 0.060 0.336 0.95 0.072 0.344 0.93
New Param. 0.013 0.240 0.97 0.006 0.185 0.98 0.022 0.146 0.97
σ = (0.5, 0.5, 0.5),ρ = 0.4
Univariate 0.009 0.225 0.96 0.101 0.356 0.77 0.079 0.341 0.80
Original 0.012 0.236 0.97 0.058 0.332 0.95 0.066 0.326 0.93
New Param. 0.013 0.239 0.97 0.012 0.196 0.98 0.024 0.150 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.8
Univariate 0.009 0.225 0.96 0.112 0.364 0.73 0.084 0.338 0.73
Original 0.011 0.232 0.96 0.052 0.312 0.95 0.056 0.295 0.92
New Param. 0.012 0.237 0.97 0.017 0.202 0.97 0.025 0.150 0.94
σ = (0.5, 1, 1),ρ = 0
Univariate 0.009 0.226 0.96 0.103 0.417 0.86 0.100 0.432 0.90
Original 0.013 0.238 0.97 0.090 0.438 0.94 0.117 0.465 0.92
New Param. 0.013 0.238 0.97 0.006 0.210 0.98 0.029 0.175 0.96
σ = (0.5, 1, 1),ρ = 0.4
Univariate 0.009 0.225 0.96 0.120 0.428 0.81 0.112 0.440 0.84
Original 0.013 0.236 0.97 0.084 0.425 0.94 0.109 0.449 0.92
New Param. 0.013 0.237 0.97 0.014 0.224 0.97 0.034 0.184 0.95
σ = (0.5, 1, 1),ρ = 0.8
Univariate 0.009 0.224 0.95 0.137 0.430 0.74 0.117 0.432 0.77
Original 0.011 0.232 0.96 0.069 0.385 0.94 0.082 0.386 0.92
New Param. 0.012 0.234 0.96 0.021 0.234 0.95 0.034 0.189 0.93
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Table A.6: (N = 30, ni = 100, No Missing Data) Bias, 95% credible interval width (CIW)
and coverage probability (Cov.) for univariate model, original multivariate model, and new
parameterization across 2000 simulations containing 30 studies, where ni = 100, the true
prevalences are (0.3, 0.15, 0.05), and the data are fully observed.
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5),ρ = 0
Univariate 0.003 0.121 0.95 0.004 0.081 0.96 0.003 0.044 0.95
Original 0.003 0.123 0.96 0.005 0.083 0.96 0.004 0.045 0.95
New Param. 0.004 0.124 0.96 0.002 0.081 0.96 0.003 0.043 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.4
Univariate 0.003 0.121 0.95 0.005 0.092 0.96 0.004 0.051 0.96
Original 0.003 0.123 0.96 0.006 0.094 0.96 0.005 0.052 0.96
New Param. 0.004 0.124 0.96 0.004 0.092 0.96 0.004 0.050 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.8
Univariate 0.003 0.121 0.96 0.005 0.102 0.96 0.005 0.058 0.96
Original 0.006 0.134 0.95 0.009 0.119 0.95 0.008 0.073 0.95
New Param. 0.003 0.122 0.96 0.005 0.100 0.96 0.004 0.054 0.95
σ = (0.5, 1, 1),ρ = 0
Univariate 0.003 0.121 0.96 0.006 0.104 0.96 0.007 0.071 0.96
Original 0.004 0.124 0.96 0.008 0.106 0.96 0.009 0.075 0.96
New Param. 0.005 0.125 0.96 0.003 0.099 0.96 0.005 0.063 0.96
σ = (0.5, 1, 1),ρ = 0.4
Univariate 0.003 0.121 0.96 0.007 0.118 0.96 0.009 0.082 0.96
Original 0.004 0.123 0.96 0.008 0.119 0.97 0.010 0.084 0.96
New Param. 0.005 0.125 0.96 0.005 0.112 0.96 0.007 0.073 0.96
σ = (0.5, 1, 1),ρ = 0.8
Univariate 0.003 0.121 0.96 0.008 0.131 0.96 0.010 0.090 0.96
Original 0.003 0.122 0.96 0.008 0.130 0.96 0.010 0.088 0.96
New Param. 0.003 0.122 0.96 0.006 0.122 0.95 0.008 0.079 0.96
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Table A.7: (N = 10, ni = 100, No Missing Data) Bias, 95% credible interval width (CIW)
and coverage probability (Cov.) for univariate model, original multivariate model, and new
parameterization across 2000 simulations containing 10 studies, where ni = 100, the true
prevalences are (0.3, 0.15, 0.05), and the data are fully observed.
Overall Subtype 1 Subtype 2
Bias CIW Cov. Bias CIW Cov. Bias CIW Cov.
σ = (0.5, 0.5, 0.5),ρ = 0
Univariate 0.008 0.224 0.96 0.012 0.165 0.96 0.013 0.113 0.96
Original 0.011 0.235 0.97 0.016 0.175 0.96 0.016 0.125 0.95
New Param. 0.013 0.244 0.97 0.007 0.166 0.97 0.010 0.104 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.4
Univariate 0.007 0.223 0.95 0.015 0.185 0.95 0.016 0.133 0.96
Original 0.009 0.231 0.96 0.017 0.193 0.96 0.019 0.141 0.96
New Param. 0.012 0.240 0.97 0.011 0.183 0.96 0.013 0.118 0.96
σ = (0.5, 0.5, 0.5),ρ = 0.8
Univariate 0.007 0.222 0.96 0.016 0.203 0.96 0.020 0.153 0.96
Original 0.009 0.231 0.96 0.019 0.212 0.97 0.021 0.155 0.96
New Param. 0.010 0.233 0.97 0.014 0.196 0.96 0.016 0.131 0.96
σ = (0.5, 1, 1),ρ = 0
Univariate 0.007 0.224 0.96 0.017 0.209 0.97 0.029 0.194 0.97
Original 0.011 0.241 0.97 0.024 0.226 0.97 0.040 0.221 0.95
New Param. 0.013 0.246 0.97 0.005 0.194 0.97 0.018 0.147 0.97
σ = (0.5, 1, 1),ρ = 0.4
Univariate 0.006 0.224 0.96 0.020 0.236 0.97 0.034 0.216 0.97
Original 0.009 0.236 0.97 0.026 0.247 0.97 0.042 0.233 0.96
New Param. 0.011 0.242 0.97 0.010 0.214 0.98 0.023 0.166 0.97
σ = (0.5, 1, 1),ρ = 0.8
Univariate 0.006 0.223 0.96 0.023 0.259 0.97 0.038 0.235 0.97
Original 0.007 0.229 0.97 0.025 0.260 0.97 0.038 0.232 0.97
New Param. 0.008 0.232 0.97 0.014 0.230 0.97 0.025 0.180 0.97
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Table A.8: Case Study Results with Inverse Wishart Prior
Model UI CIW SUI CIW UUI CIW
Univariate 0.274 (0.024) 0.096 0.127 (0.022) 0.088 0.066 (0.021) 0.082
Multivariate 0.273 (0.023) 0.090 0.123 (0.019) 0.075 0.058 (0.014) 0.056
New Parameterization 0.273 (0.023) 0.090 0.122 (0.018) 0.069 0.057 (0.014) 0.053
(a) Posterior mean (SD) of marginal prevalences for overall outcome (UI) and two subtypes (SUI, UUI) with
corresponding 95% credible interval width (CIW)
σ̂1 σ̂2 σ̂3
Univariate 0.383 (0.06) 0.435 (0.089) 0.607 (0.131)






New Param. 0.363 (0.053) 0.641 (0.117) 0.567 (0.111)
ρ̂12 ρ̂13 ρ̂23






New Param. -0.11 (0.251) 0.396 (0.231) 0.093 (0.273)
(b) Posterior mean (SD) of components in estimated covariance matrices for original




“Estimating the Reference Range from
a Meta-Analysis”
B.1 Method of moments estimators for lognormal distribution
In (3.9), we use the method of moments estimators for the location and scale parameters of
the lognormal distribution in order to transform the observed mean and variance to the log
scale, where the observations would be normally distributed. Suppose Y = {y1, ..., yn} ∼
Lognormal(µ, σ2). Then the first two moments of the lognormal distribution are given
by [96]:




























Solving for µ and σ2, we have:
µ̂MM = log
 ȳ2√


























where s2 = 1n−1
∑n
i=1 (yi − ȳ)
2.

















We can then treat ȳ∗i and s
2∗
i as approximations of the sample mean and sample variance
of the study on the log scale.
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B.2 Figures































Supplementary Materials for “A Guide
to Estimating the Reference Range
from a Meta-Analysis using Aggregate
or Individual Participant Data”
C.1 Methods for Estimating the Reference Range
C.1.1 Frequentist approach using a random-effects model
Aggregate data
The first method we proposed uses the results of a frequentist random-effects model, which
assumes that the underlying study means in the meta-analysis follow a normal distribution
with mean µRE and variance τ
2. We then add the additional assumptions that the data
within each study are normally distributed and that the within-study variance (σ2) is con-
stant across studies. This implies that each of the individuals included in the meta-analysis
are marginally distributed N(µRE , σ
2 + τ2). To estimate the reference range, first estimate
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the pooled mean across all studies (µRE) and the between-study variation (τ
2) using a fre-
quentist random-effects model. We use the restricted maximum likelihood (REML) model
implemented in the R package “meta” [75], but other methods and software could also be
used. Next, use the pooled sample variance as an estimate of the common within-study
variance (Table 4.1). Finally, the bounds of an (1 − α)100% level reference range can be
estimated by the α/2 and 1− α/2 quantiles of a N(µRE , σ2 + τ2) distribution (Table 4.1).
Individual participant data
If individual participant data are available, any of the methods based on aggregate data
described in this guide can still be used by first aggregating the data by study to get the
study means, standard deviations, and sample sizes. However, a frequentist random effects
model (linear mixed model) can also be fit directly using the individual participant data
without first aggregating. We use the R package “lme4,” but many other choices of software
are available. Let τ2 be the estimated variance of the random effects, σ2 be the estimated
residual variance, and µRE be the estimated pooled mean from the model. Then, the bounds
of an (1-α)100% level reference range can be estimated by the α/2 and 1 - α/2 quantiles of
a N(µRE , σ
2 + τ2) distribution (Table 4.1).
C.1.2 Bayesian posterior predictive interval
Aggregate data
The second method we proposed uses the posterior predictive distribution of a new individ-
ual from a Bayesian random-effects model. This imposes the same distributional assump-
tions as with the frequentist approach. The sampling distributions of the study-means and
standard deviations can be used to estimate the posterior distributions of µRE , σ
2, and τ2
using Markov Chain Monte Carlo sampling (Table 4.1). An (1-α)100% level reference range
can then be estimated by the α/2 and 1 - α/2 quantiles of samples from a N(µRE , σ
2 + τ2)
distribution, the posterior predictive distribution for a new individual. We place a N(0,
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1000) prior on µRE , and Uniform(0,100) priors on σ and τ , as shown in Table 4.1. The
main difference between this and the frequentist methods is that the posterior predictive
interval incorporates the uncertainty in the estimated parameters into the reference range,
whereas the frequentist methods do not.
Individual participant data
However, if individual participant data are available, a Bayesian random effects model can
also be fit directly on the individual observations, just as with the frequentist approach.
Instead of using the sampling distributions for the study means and standard deviations,
we can use the likelihood for an individual observation (Table 4.1). We still place the
same priors on each of the estimated parameters, and the resulting range has the same
interpretation as the posterior predictive interval based on the aggregate data.
C.1.3 Empirical approach
Aggregate data
Finally, we proposed a simple empirical approach using aggregate data, which is similar to
the method used by Conceição et al. [9] to estimate reference ranges for normal Subjective
Postural Vertical (SPV) measurements. This does not make the same assumption about
constant within-study variance, but still assumes the data are normally distributed. First,
empirically estimate the pooled mean (µemp), weighting by the sample size in each study.
This is equivalent to the mean estimate in the fixed effects model proposed by Laird and
Mosteller [64] when weighting by sample size. Then, estimate the total variance both
within and across studies (σ2T ) (Table 4.1). An (1-α)100% level reference range can then be





If individual participant data are available, one could equivalently pool the data across
studies and estimate the pooled mean (µemp) as the mean of these individual measurements.
The total variance within and across studies could similarly be estimated as the variance
of these pooled samples (σ2T ) (Table 4.1). Then, an (1-α)100% level reference range can be
estimated by the α/2 and 1 - α/2 quantiles of a N(µemp, σ
2
T ) distribution.
C.2 Lognormally distributed data
In some cases, such as when a measurement cannot take on negative values, it may be
more reasonable to assume that the data within each study follow a lognormal distribution.
If individual participant data are available, the preferred approach would be to first log-
transform the individual observations, estimate the reference interval, then exponentiate
the resulting bounds. However, if only aggregate data are available, the observed means
and standard deviations need to be transformed to the log scale. Suppose Y = {y1, . . . , yn}
denotes a set of continuous observations. Because, 1n
∑n








observed means and sample variances on the log-scale must be estimated. The method of
moments estimators for the mean and variance of log(Y) are given in Table 4.3. These
equations can be used to estimate the observed means and sample variances, which can
then be used in each of the methods described to estimate the reference range. Finally,
the resulting range can be exponentiated in order to return to the original scale. We note
that when performing either of these transformations, the normality assumption for the
study means now applies to the log-transformed data and should be still be assessed using
methods such as a normal Q-Q plot, as the transformed means may be skewed.
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Let 𝑦𝑖!!! , 𝑠!" , and 𝑛𝑖 be the sample mean, sample variance, and sample size for study i, 
respectively. The method of moments estimators for the location and scale parameters of 































We can then use 𝑦"$∗ and 𝑠$%
∗ as estimates of the mean and sample standard deviation on the 
log scale when individual participant data are not available. 
 














Table C.2: Aggregate Data for Liver Stiffness Example
Study Mean SD Sample Size
1 1.00 4.66 1.38 581
2 2.00 4.11 0.89 530
3 3.00 3.97 1.00 67
4 4.00 4.57 1.29 248
5 5.00 4.53 1.30 206
6 6.00 4.99 1.08 183
7 7.00 4.20 1.18 60
8 8.00 4.67 1.18 35
9 9.00 5.05 4.42 34
10 10.00 4.82 1.22 132
11 11.00 5.20 1.39 420
12 12.00 4.83 1.25 90
13 13.00 5.09 1.18 433
14 14.00 4.52 1.51 498
15 15.00 5.45 1.87 52
16 16.00 5.18 0.68 29
17 17.00 5.17 1.13 9
18 18.00 3.83 0.67 15
19 19.00 4.36 1.37 26
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Table C.3: Sensitivity Analysis with Aggregate Data Results when removing studies 9 and
16 and estimating reference ranges using aggregate data.
95% Reference Range
Frequentist AD (2.58, 7.74)
Bayesian AD (2.57, 7.84)
Empirical AD (2.61, 7.75)
Table C.4: Sensitivity Analysis with IPD Results when removing studies 9 and 16 and
estimating reference ranges using IPD.
95% Reference Range
Frequentist AD (2.62, 7.74)
Bayesian AD (2.61, 7.79)
Empirical AD (2.64, 7.69)
Frequentist IPD (2.63, 7.72)
Bayesian IPD (2.52, 7.94)
Empirical IPD (2.64, 7.69)
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C.3.2 Figures
Figure C.1: Forest Plot of Study Standard Deviations from Clinical Scenario Standard
deviations of the log of liver stiffness measurements for each study and corresponding 95%
confidence intervals. The observed standard deviations in studies 9 and 16 look as though
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Figure C.2: Normal Q-Q plot of log-transformed means of liver stiffness
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Figure C.4: Histograms of the log-transformed liver stiffness measurements by study.
16 17 18 19
11 12 13 14 15
6 7 8 9 10
1 2 3 4 5


















Liver Stiffness Measurement (kPa) by Study
C
ou
nt
119
